<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32143</article-id><article-id pub-id-type="doi">10.7554/eLife.32143</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-97390"><name><surname>Springer</surname><given-names>Simeon U</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2891-2111</contrib-id><email>gnetto@uabmc.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-99077"><name><surname>Chen</surname><given-names>Chung-Hsin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-99065"><name><surname>Rodriguez Pena</surname><given-names>Maria Del Carmen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3439-7013</contrib-id><email>mdcrodriguez@uabmc.edu</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99041"><name><surname>Li</surname><given-names>Lu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1920-4965</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99400"><name><surname>Douville</surname><given-names>Christopher</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2510-4151</contrib-id><email>cdouvil1@jhmi.edu</email><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99043"><name><surname>Wang</surname><given-names>Yuxuan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2932-6042</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99044"><name><surname>Cohen</surname><given-names>Joshua David</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1158-5668</contrib-id><email>cohen@jhmi.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99192"><name><surname>Taheri</surname><given-names>Diana</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-52248"><name><surname>Silliman</surname><given-names>Natalie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99047"><name><surname>Schaefer</surname><given-names>Joy</given-names></name><email>mjschaefer68@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99048"><name><surname>Ptak</surname><given-names>Janine</given-names></name><email>jptak1@jhmi.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99049"><name><surname>Dobbyn</surname><given-names>Lisa</given-names></name><email>ldobbyn1@jhmi.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99050"><name><surname>Papoli</surname><given-names>Maria</given-names></name><email>mpopoli81@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99051"><name><surname>Kinde</surname><given-names>Isaac</given-names></name><email>ik@jhmi.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99045"><name><surname>Afsari</surname><given-names>Bahman</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99193"><name><surname>Tregnago</surname><given-names>Aline C</given-names></name><email>tregnago.aline@gmail.com</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99194"><name><surname>Bezerra</surname><given-names>Stephania M</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99195"><name><surname>VandenBussche</surname><given-names>Christopher</given-names></name><email>cjvand@jhmi.edu</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-74424"><name><surname>Fujita</surname><given-names>Kazutoshi</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99196"><name><surname>Ertoy</surname><given-names>Dilek</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99197"><name><surname>Cunha</surname><given-names>Isabela W</given-names></name><email>iwerneck0210@gmail.com</email><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99198"><name><surname>Yu</surname><given-names>Lijia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6735-9569</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99200"><name><surname>Bivalacqua</surname><given-names>Trinity J</given-names></name><email>tbivala1@jhmi.edu</email><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99059"><name><surname>Grollman</surname><given-names>Arthur P</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-4613"><name><surname>Diaz</surname><given-names>Luis A</given-names></name><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-99054"><name><surname>Karchin</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con26"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-106505"><name><surname>Danilova</surname><given-names>Ludmila</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con27"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99078"><name><surname>Huang</surname><given-names>Chao-Yuan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con28"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99053"><name><surname>Shun</surname><given-names>Chia-Tung</given-names></name><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="fn" rid="con29"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99216"><name><surname>Turesky</surname><given-names>Robert J</given-names></name><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="aff" rid="aff20">20</xref><xref ref-type="fn" rid="con30"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99080"><name><surname>Yun</surname><given-names>Byeong Hwa</given-names></name><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="aff" rid="aff20">20</xref><xref ref-type="fn" rid="con31"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99217"><name><surname>Rosenquist</surname><given-names>Thomas A</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con32"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-99058"><name><surname>Pu</surname><given-names>Yeong-Shiau</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con33"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35604"><name><surname>Hruban</surname><given-names>Ralph H</given-names></name><email>rhruban@jhmi.edu</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con34"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-34389"><name><surname>Tomasetti</surname><given-names>Cristian</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con35"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-52254"><name><surname>Papadopoulos</surname><given-names>Nickolas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con36"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-37789"><name><surname>Kinzler</surname><given-names>Ken W</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con37"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-59642"><name><surname>Vogelstein</surname><given-names>Bert</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0766-3854</contrib-id><email>bertvog@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con38"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes" id="author-99060"><name><surname>Dickman</surname><given-names>Kathleen G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1308-2992</contrib-id><email>kathleen.dickman@stonybrook.edu</email><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con39"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-87347"><name><surname>Netto</surname><given-names>George J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3915-9134</contrib-id><email>gnetto@uabmc.edu</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con40"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Howard Hughes Medical Institute, Ludwig Center for Cancer Genetics and Therapeutics</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Sidney Kimmel Comprehensive Cancer Center</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Urology</institution><institution>National Taiwan University Hospital</institution><addr-line><named-content content-type="city">Taipei</named-content></addr-line><country>Taiwan</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Pathology</institution><institution>Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Department of Pathology</institution><institution>University of Alabama at Birmingham</institution><addr-line><named-content content-type="city">Birmingham</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Department of Biostatistics</institution><institution>Johns Hopkins Bloomberg School of Public Health</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Department of Biomedical Engineering, Institute for Computational Medicine</institution><institution>Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">Department of Pathology, Isfahan Kidney Diseases Research Center</institution><institution>Isfahan University of Medical Sciences</institution><addr-line><named-content content-type="city">Isfahan</named-content></addr-line><country>Iran</country></aff><aff id="aff9"><label>9</label><institution content-type="dept">Department of Oncology</institution><institution>Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution content-type="dept">Division of Biostatistics and Bioinformatics, Department of Oncology, Sidney Kimmel Cancer Center</institution><institution>Johns Hopkins School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution content-type="dept">Department of Pathology</institution><institution>AC Camargo Cancer Center</institution><addr-line><named-content content-type="city">Sao Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff12"><label>12</label><institution content-type="dept">Department of Pathology</institution><institution>Osaka University</institution><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff><aff id="aff13"><label>13</label><institution content-type="dept">Department of Pathology</institution><institution>Hacettepe University</institution><addr-line><named-content content-type="city">Ankara</named-content></addr-line><country>Turkey</country></aff><aff id="aff14"><label>14</label><institution content-type="dept">Department of Urology</institution><institution>Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff15"><label>15</label><institution content-type="dept">Department of Pharmacological Sciences</institution><institution>Stony Brook University</institution><addr-line><named-content content-type="city">Stony Brook</named-content></addr-line><country>United States</country></aff><aff id="aff16"><label>16</label><institution content-type="dept">Department of Medicine</institution><institution>Stony Brook University</institution><addr-line><named-content content-type="city">Stony Brook</named-content></addr-line><country>United States</country></aff><aff id="aff17"><label>17</label><institution content-type="dept">Department of Medicine</institution><institution>Memorial Sloan Kettering Cancer Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff18"><label>18</label><institution content-type="dept">Department of Forensic Medicine and Pathology</institution><institution>National Taiwan University Hospital</institution><addr-line><named-content content-type="city">Taipei</named-content></addr-line><country>Taiwan</country></aff><aff id="aff19"><label>19</label><institution content-type="dept">Masonic Cancer Center</institution><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff20"><label>20</label><institution content-type="dept">Department of Medicinal Chemistry</institution><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Levine</surname><given-names>Ross L</given-names></name><role>Reviewing Editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>20</day><month>03</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e32143</elocation-id><history><date date-type="received" iso-8601-date="2017-09-20"><day>20</day><month>09</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2018-02-19"><day>19</day><month>02</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Springer et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Springer et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-32143-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.32143.001</object-id><p>Current non-invasive approaches for detection of urothelial cancers are suboptimal. We developed a test to detect urothelial neoplasms using DNA recovered from cells shed into urine. UroSEEK incorporates massive parallel sequencing assays for mutations in 11 genes and copy number changes on 39 chromosome arms. In 570 patients at risk for bladder cancer (BC), UroSEEK was positive in 83% of those who developed BC. Combined with cytology, UroSEEK detected 95% of patients who developed BC. Of 56 patients with upper tract urothelial cancer, 75% tested positive by UroSEEK, including 79% of those with non-invasive tumors. UroSEEK detected genetic abnormalities in 68% of urines obtained from BC patients under surveillance who demonstrated clinical evidence of recurrence. The advantages of UroSEEK over cytology were evident in low-grade BCs; UroSEEK detected 67% of cases whereas cytology detected none. These results establish the foundation for a new non-invasive approach for detection of urothelial cancer.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>liquid biopsy</kwd><kwd>cancer</kwd><kwd>urine</kwd><kwd>bladder</kwd><kwd>renal pelvis</kwd><kwd>ureter</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001868</institution-id><institution>National Science Council</institution></institution-wrap></funding-source><award-id>104-2314-B-002-132</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Chung-Hsin</given-names></name><name><surname>Pu</surname><given-names>Yeong-Shiau</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001868</institution-id><institution>National Science Council</institution></institution-wrap></funding-source><award-id>104-2314-B-002-121-MY3</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Chung-Hsin</given-names></name><name><surname>Pu</surname><given-names>Yeong-Shiau</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Wang</surname><given-names>Yuxuan</given-names></name><name><surname>Grollman</surname><given-names>Arthur P</given-names></name><name><surname>Kinzler</surname><given-names>Ken W</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Henry and Marsha Laufer</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Grollman</surname><given-names>Arthur P</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000925</institution-id><institution>John Templeton Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Tomasetti</surname><given-names>Cristian</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000910</institution-id><institution>Conrad N. Hilton Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Papadopoulos</surname><given-names>Nickolas</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009729</institution-id><institution>Ludwig Institute for Cancer Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kinzler</surname><given-names>Ken W</given-names></name><name><surname>Vogelstein</surname><given-names>Bert</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Sol Goldman Pancreatic Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Vogelstein</surname><given-names>Bert</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The creation of a non-invasive assay for detecting urothelial cancer could have a profound impact on how we find and treat the disease.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Bladder cancer (BC) is the most common malignancy of the urinary tract. According to the American Cancer Society, 79,030 new cases of bladder cancer and 18,540 deaths were estimated to occur in the United States alone in 2017 (<xref ref-type="bibr" rid="bib79">Siegel et al., 2017</xref>). Predominantly of urothelial histology, invasive BC arises from non-invasive papillary or flat precursors, and many BC patients suffer multiple relapses prior to progression, providing ample lead-time for early detection and treatment prior to metastasis (<xref ref-type="bibr" rid="bib61">Netto, 2013</xref>).</p><p>Although most urothelial carcinomas arise in the bladder, 5–10% originate in the renal pelvis and/or ureter (<xref ref-type="bibr" rid="bib69">Rouprêt et al., 2015</xref>; <xref ref-type="bibr" rid="bib81">Soria et al., 2017</xref>). The annual incidence of these upper tract urothelial carcinomas (UTUC) in Western countries is 1–2 cases per 100,000 (<xref ref-type="bibr" rid="bib69">Rouprêt et al., 2015</xref>; <xref ref-type="bibr" rid="bib81">Soria et al., 2017</xref>), but the disease occurs at a much higher rate in populations exposed to aristolochic acid (AA) (<xref ref-type="bibr" rid="bib9">Chen et al., 2012</xref>; <xref ref-type="bibr" rid="bib26">Grollman, 2013</xref>; <xref ref-type="bibr" rid="bib45">Lai et al., 2010</xref>; <xref ref-type="bibr" rid="bib84">Taiwan Cancer Registry, 2017</xref>). AA is a carcinogenic and nephrotoxic nitrophenanthrene carboxylic acid produced by <italic>Aristolochia</italic> plants (<xref ref-type="bibr" rid="bib58">National Toxicology Program, 2011</xref>). An etiological link between AA exposure and UTUC has been established in several populations (<xref ref-type="bibr" rid="bib26">Grollman, 2013</xref>; <xref ref-type="bibr" rid="bib25">Grollman et al., 2009</xref>; <xref ref-type="bibr" rid="bib37">Jelaković et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">National Toxicology Program, 2011</xref>). The profound public health threat posed by the medicinal use of <italic>Aristolochia</italic> herbs is illustrated in Taiwan, which has the highest incidence of UTUC in the world (<xref ref-type="bibr" rid="bib9">Chen et al., 2012</xref>; <xref ref-type="bibr" rid="bib95">Yang et al., 2002</xref>). In recent years, more than one-third of the adult population in Taiwan has been prescribed herbal remedies containing AA (<xref ref-type="bibr" rid="bib32">Hsieh et al., 2008</xref>), resulting in an unusually high (37%) proportion of UTUC cases relative to urothelial cancers worldwide (<xref ref-type="bibr" rid="bib84">Taiwan Cancer Registry, 2017</xref>).</p><p>Tumors of the upper and lower urinary tracts differ in important ways, including etiology, but they have many common features (<xref ref-type="bibr" rid="bib24">Green et al., 2013</xref>), such as the somatic alterations that drive their growth (<xref ref-type="bibr" rid="bib46">Lee et al., 2018</xref>). High rates of activating mutations in the upstream promoter of the <italic>TERT</italic> gene are found in the majority of urothelial neoplasms of both upper and lower tracts (<xref ref-type="bibr" rid="bib34">Huang et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Killela et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Scott et al., 2014</xref>; <xref ref-type="bibr" rid="bib96">Yuan et al., 2016</xref>). <italic>TERT</italic> promoter mutations predominantly affect two hot spots, g.1295228 C &gt; T and g.1295250 C &gt; T. These mutations generate CCGGAA/T or GGAA/T motifs that alter the binding site for ETS transcription factors and subsequently stimulate increased <italic>TERT</italic> promoter activity (<xref ref-type="bibr" rid="bib31">Horn et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Huang et al., 2013</xref>). <italic>TERT</italic> promoter mutations occur in up to 80% of invasive urothelial carcinomas of the bladder and in several of their histologic variants (<xref ref-type="bibr" rid="bib1">Allory et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Cowan et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Killela et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Kinde et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Nguyen et al., 2016</xref>). Moreover, <italic>TERT</italic> promoter mutations occur in 60–80% of BC precursors, including papillary urothelial neoplasms of low malignant potential (<xref ref-type="bibr" rid="bib68">Rodriguez Pena et al., 2017</xref>), non-invasive low-grade papillary urothelial carcinoma, non-invasive high-grade papillary urothelial carcinoma and ‘flat’ carcinoma in situ (CIS), as well as in urinary cells from a subset of these patients (<xref ref-type="bibr" rid="bib43">Kinde et al., 2013</xref>). <italic>TERT</italic> promoter mutations have thus been established as a common genetic alteration in urothelial neoplasms (<xref ref-type="bibr" rid="bib11">Cheng et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">Killela et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Kinde et al., 2013</xref>; <xref ref-type="bibr" rid="bib96">Yuan et al., 2016</xref>).</p><p>Other important oncogene-activating mutations include those in <italic>FGFR3</italic>, <italic>RAS</italic> and <italic>PIK3CA</italic> genes, which occur in a high fraction of non-muscle invasive bladder cancers (<xref ref-type="bibr" rid="bib35">Humphrey et al., 2016</xref>; <xref ref-type="bibr" rid="bib60">Netto, 2011</xref>). In muscle-invasive bladder cancers, mutations in the <italic>TP53, CDKN2A, MLL</italic> and <italic>ERBB2</italic> genes are also frequently found (<xref ref-type="bibr" rid="bib7">Cancer Genome Atlas Research Network, 2014</xref>; <xref ref-type="bibr" rid="bib50">Lin et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Mo et al., 2007</xref>; <xref ref-type="bibr" rid="bib60">Netto, 2011</xref>; <xref ref-type="bibr" rid="bib72">Sarkis et al., 1995</xref>; <xref ref-type="bibr" rid="bib71">Sarkis et al., 1994</xref>; <xref ref-type="bibr" rid="bib70">Sarkis et al., 1993</xref>; <xref ref-type="bibr" rid="bib93">Wu, 2005</xref>). Mutations in these genes are also present in UTUC (<xref ref-type="bibr" rid="bib29">Hoang et al., 2013</xref>; <xref ref-type="bibr" rid="bib46">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">Moss et al., 2017</xref>; <xref ref-type="bibr" rid="bib76">Sfakianos et al., 2015</xref>).</p><p>Urine cytology is a non-invasive method for the detection of BC. Although it has value for the detection of high-grade BC, the test is unable to detect the vast majority of low-grade tumors (<xref ref-type="bibr" rid="bib51">Lotan and Roehrborn, 2003</xref>; <xref ref-type="bibr" rid="bib62">Netto and Tafe, 2016</xref>; <xref ref-type="bibr" rid="bib98">Zhang et al., 2016</xref>). Urine cytology also fails to detect the majority of UTUCs (<xref ref-type="bibr" rid="bib2">Baard et al., 2017</xref>). These facts, together with the high cost and invasive nature of repeated endoscopy and follow-up biopsy procedures, have led to many attempts to develop alternative minimally invasive methods to detect urothelial cancers. Strategies to identify BC include urine- or serum-based genetic and protein assays for screening and surveillance (<xref ref-type="bibr" rid="bib1">Allory et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Bansal et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Ellinger et al., 2015</xref>; <xref ref-type="bibr" rid="bib20">Fradet and Lockhard, 1997</xref>; <xref ref-type="bibr" rid="bib22">Goodison et al., 2012</xref>; <xref ref-type="bibr" rid="bib36">Hurst et al., 2014</xref>; <xref ref-type="bibr" rid="bib38">Kawauchi et al., 2009</xref>; <xref ref-type="bibr" rid="bib43">Kinde et al., 2013</xref>; <xref ref-type="bibr" rid="bib44">Krüger et al., 2003</xref>; <xref ref-type="bibr" rid="bib55">Moonen et al., 2007</xref>; <xref ref-type="bibr" rid="bib66">Ralla et al., 2014</xref>; <xref ref-type="bibr" rid="bib73">Sarosdy et al., 2006</xref>; <xref ref-type="bibr" rid="bib75">Serizawa et al., 2011</xref>; <xref ref-type="bibr" rid="bib80">Skacel et al., 2003</xref>; <xref ref-type="bibr" rid="bib88">Wang et al., 2014</xref>; <xref ref-type="bibr" rid="bib94">Yafi et al., 2015</xref>). Currently available U.S. Food and Drug Administration (FDA) approved assays for BC diagnosis include the ImmunoCyt test (Scimedx Corp), the nuclear matrix protein 22 (NMP22) immunoassay test (Matritech), and multitarget FISH (UroVysion) (<xref ref-type="bibr" rid="bib20">Fradet and Lockhard, 1997</xref>; <xref ref-type="bibr" rid="bib38">Kawauchi et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">Krüger et al., 2003</xref>; <xref ref-type="bibr" rid="bib55">Moonen et al., 2007</xref>; <xref ref-type="bibr" rid="bib73">Sarosdy et al., 2006</xref>; <xref ref-type="bibr" rid="bib80">Skacel et al., 2003</xref>; <xref ref-type="bibr" rid="bib94">Yafi et al., 2015</xref>). Sensitivities between 62% and 69% and specificities between 79% and 89% have been reported for some of these tests. However, due to assay performance inconsistencies, cost or requirements for technical expertise, integration of such assays into routine clinical practice has not yet occurred. Furthermore, none of the FDA-approved BC assays have yet been validated for clinical use in detection of UTUC. Therefore, a non-invasive test that predicts which patients are most likely to develop urothelial cancer could be medically and economically important.</p><p>As urothelial cells from the upper and lower urinary tracts are in direct contact with urine, we hypothesized that genetic analyses of exfoliated urinary cells could be used to detect neoplasia in these organs in a non-invasive fashion. The current study assesses the performance of a massively parallel sequencing-based assay, termed UroSEEK, for the detection of BC and UTUC through the genetic analysis of urinary cell DNA. UroSEEK has three components: detection of intragenic mutations in regions of ten genes (<italic>FGFR3, TP53, CDKN2A, ERBB2, HRAS, KRAS, PIK3CA, MET, VHL and MLL</italic>) frequently mutated in urothelial tumors (<xref ref-type="bibr" rid="bib7">Cancer Genome Atlas Research Network, 2014</xref>; <xref ref-type="bibr" rid="bib29">Hoang et al., 2013</xref>; <xref ref-type="bibr" rid="bib46">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Lin et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Mo et al., 2007</xref>; <xref ref-type="bibr" rid="bib57">Moss et al., 2017</xref>; <xref ref-type="bibr" rid="bib60">Netto, 2011</xref>; <xref ref-type="bibr" rid="bib72">Sarkis et al., 1995</xref>; <xref ref-type="bibr" rid="bib71">Sarkis et al., 1994</xref>; <xref ref-type="bibr" rid="bib70">Sarkis et al., 1993</xref>; <xref ref-type="bibr" rid="bib76">Sfakianos et al., 2015</xref>; <xref ref-type="bibr" rid="bib93">Wu, 2005</xref>); detection of mutations in the <italic>TERT</italic> promoter (<xref ref-type="bibr" rid="bib34">Huang et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Killela et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Scott et al., 2014</xref>; <xref ref-type="bibr" rid="bib96">Yuan et al., 2016</xref>); and detection of aneuploidy (<xref ref-type="bibr" rid="bib42">Kinde et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">Kinde et al., 2011</xref>). The exons and specific genes chosen for inclusion in UroSEEK were chosen on the basis of BC mutations recorded in the COSMIC database (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Selected amplicons from VHL and MET were also included in the hope that renal cell carcinomas might also shed cells into urine, although urine samples from patients with these cancers were not included in our study.</p><p>UroSEEK was applied to three independent cohorts of patients. The first (called the BC early detection cohort) exhibited microscopic hematuria or dysuria and supplied urine samples prior to any surgical procedures. A small fraction (4% to 5%) of patients with microscopic hematuria later develops urothelial malignancy (<xref ref-type="bibr" rid="bib92">Wein et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Mishriki et al., 2008</xref>), so the decision as to which patients should undergo cystoscopy is often difficult. The second cohort (called the UTUC cohort) consisted of Taiwanese patients with UTUC who supplied a urine sample prior to nephroureterectomy. Such patients might benefit from a non-invasive test that could be used to screen individuals at increased risk for UTUC, such as those exposed to herbal remedies containing the carcinogen AA. The third cohort (called the BC surveillance cohort) included patients who had already been diagnosed with BC and were therefore at high risk for recurrence (<xref ref-type="bibr" rid="bib92">Wein et al., 2012</xref>). Because urine cytology is relatively insensitive for the detection of recurrence, cystoscopies are performed as often as every three months in such patients in the U.S. In fact, the cost of managing these patients is in aggregate higher than the cost of managing any other type of cancer, amounting to 3 billion dollars annually (<xref ref-type="bibr" rid="bib59">Netto and Epstein, 2010</xref>).</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>A schematic of the approach used in this study is provided in <xref ref-type="fig" rid="fig1">Figure 1</xref>. A flow diagram indicating the number of patients evaluated in this study and the major results are presented in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.32143.002</object-id><label>Figure 1.</label><caption><title>Schematic of the approach used to evaluate urinary cells in this study.</title><p>UroSEEK assay is designed to detect urothelial neoplasms that are in direct contact with urine (<bold>A</bold>) of variable pathologic stages originating in upper urinary tract (<bold>B</bold>) or bladder (<bold>C</bold>).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-32143-fig1-v2"/></fig><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.32143.003</object-id><label>Figure 2.</label><caption><title>Flow diagram indicating the number of patients in the three cohorts evaluated in this study and summarizing the salient findings.</title><p>Cytology was performed on only a subset of the patients (see main text).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-32143-fig2-v2"/></fig><sec id="s2-1"><title>BC early detection cohort</title><sec id="s2-1-1"><title>Cohort characteristics</title><p>A total of 570 patients were included in the early detection cohort, each with one urine sample analyzed. 90% of the patients had hematuria, 3% had lower urinary tract symptoms (LUTS), and 9% had other indications suggesting they were at risk for BC. The median age of the participants was 58 years (range 5 to 89 years; <xref ref-type="table" rid="table1">Table 1a</xref>). As expected from prior studies of patients at risk for BC, 70% of the patients were male (<xref ref-type="bibr" rid="bib79">Siegel et al., 2017</xref>; <xref ref-type="bibr" rid="bib92">Wein et al., 2012</xref>). Patients (<italic>n</italic> = 175; 31%) developed BC after a median follow-up period of 18 months (range 0 to 40 months). For each patient who developed BC, we selected two other patients who presented with similar symptoms but did not develop BC during the follow-up period. By design, the fraction of cases in this cohort developing BC was higher than the fraction (5%) of patients with similar presentations who would have developed BC in standard clinical practice. The characteristics of the tumors developing in the 570 patients are summarized in <xref ref-type="table" rid="table1">Table 1a</xref> and detailed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p><table-wrap id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.32143.004</object-id><label>Table 1.</label><caption><title>Demographic, clinical and genetic features of the early detection cohort.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Gender</th><th>n</th><th>%</th><th>Ten-gene multiplex positive</th><th>TERT positive</th><th>Aneuploidy positive</th><th>UroSEEK positive</th><th>Cytology positive*</th><th>Uroseek or cytology positive*</th></tr></thead><tbody><tr><td colspan="9">Table 1a. Demographic, clinical and genetic features of the early detection cohort</td></tr><tr><td>Males without recurrence</td><td>172</td><td>59%</td><td>3 (2%)</td><td>10 (6%)</td><td>2 (1%)</td><td>13 (8%)</td><td valign="bottom">0 (0%)</td><td>13 (8%)</td></tr><tr><td>Males with recurrence</td><td>32</td><td>11%</td><td>26 (81%)</td><td>21 (66%)</td><td>19 (59%)</td><td>29 (91%)</td><td valign="bottom">16 (50%)</td><td>30 (94%)</td></tr><tr><td>Females without recurrence</td><td>81</td><td>28%</td><td>2 (2%)</td><td>2 (2%)</td><td>1 (1%)</td><td>5 (6%)</td><td valign="bottom">0 (0%)</td><td>5 (6%)</td></tr><tr><td>Females with recurrence</td><td>9</td><td>3%</td><td>4 (44%)</td><td>4 (44%)</td><td>3 (33%)</td><td>6 (67%)</td><td valign="bottom">1 (11%)</td><td>6 (67%)</td></tr><tr><td><italic>Indication</italic></td><td/><td/><td/><td/><td/><td/><td valign="bottom"/><td/></tr><tr><td>Hematuria without recurrence</td><td>346</td><td>61%</td><td>6 (2%)</td><td>15 (4%)</td><td>5 (1%)</td><td>22 (6%)</td><td valign="bottom">0 (0%)</td><td>17 (5%)</td></tr><tr><td>Hematuria with recurrence</td><td>163</td><td>29%</td><td>108 (66%)</td><td>90 (55%)</td><td>76 (47%)</td><td>134 (82%)</td><td valign="bottom">18 (11%)</td><td>32 (2%)</td></tr><tr><td>LUTS without recurrence</td><td>11</td><td>2%</td><td>0 (0%)</td><td>2 (18%)</td><td>0 (0%)</td><td>2 (18%)</td><td valign="bottom">0 (0%)</td><td>2 (18%)</td></tr><tr><td>LUTS with recurrence</td><td>3</td><td>1%</td><td>2 (67%)</td><td>1 (33%)</td><td>0 (0%)</td><td>2 (67%)</td><td valign="bottom">1 (33%)</td><td>2 (67%)</td></tr><tr><td>Other without recurrence</td><td>38</td><td>7%</td><td>1 (3%)</td><td>0 (0%)</td><td>1 (3%)</td><td>2 (5%)</td><td valign="bottom">0 (0%)</td><td>2 (5%)</td></tr><tr><td>Other with recurrence</td><td>9</td><td>2%</td><td>9 (100%)</td><td>8 (89%)</td><td>5 (56%)</td><td>9 (100%)</td><td valign="bottom">2 (22%)</td><td>9 (100%)</td></tr><tr><td><italic>Detected Tumor Diagnosis</italic></td><td valign="bottom"/><td valign="bottom"/><td/><td/><td/><td/><td valign="bottom"/><td valign="bottom"/></tr><tr><td>PUNLMP</td><td>2</td><td>1%</td><td>0 (0%)</td><td>1 (50%)</td><td>0 (0%)</td><td>1 (50%)</td><td valign="bottom">0 (0%)</td><td>0 (0%)</td></tr><tr><td>CIS</td><td>7</td><td>5%</td><td>4 (57%)</td><td>4 (57%)</td><td>1 (14%)</td><td>6 (86%)</td><td valign="bottom">3 (43%)</td><td>6 (86%)</td></tr><tr><td>LGTCC</td><td>31</td><td>21%</td><td>15 (48%)</td><td>18 (58%)</td><td>9 (29%)</td><td>22 (71%)</td><td valign="bottom">0 (0%)</td><td>4 (13%)</td></tr><tr><td>HGTCC</td><td>49</td><td>33%</td><td>34 (69%)</td><td>28 (57%)</td><td>26 (53%)</td><td>40 (82%)</td><td valign="bottom">4 (8%)</td><td>11 (22%)</td></tr><tr><td>INTCC</td><td>61</td><td>41%</td><td>48 (79%)</td><td>36 (59%)</td><td>35 (57%)</td><td>57 (93%)</td><td valign="bottom">9 (15%)</td><td>16 (26%)</td></tr><tr><td><italic>Cytology diagnosis*</italic></td><td/><td/><td/><td/><td/><td/><td valign="bottom"/><td valign="bottom"/></tr><tr><td>Positive</td><td>21</td><td>6%</td><td>16 (76%)</td><td>12 (57%)</td><td>16 (76%)</td><td>20 (95%)</td><td>N/A</td><td>N/A</td></tr><tr><td>Atypical</td><td>105</td><td>30%</td><td>21 (20%)</td><td>21 (30%)</td><td>12 (11%)</td><td>30 (29%)</td><td>N/A</td><td>N/A</td></tr><tr><td valign="top">Negative</td><td valign="top">221</td><td valign="top">64%</td><td valign="top">4 (2%)</td><td valign="top">9 (4%)</td><td valign="top">1 (0.4%)</td><td valign="top">12 (5%)</td><td valign="top">N/A</td><td valign="top">N/A</td></tr><tr><td colspan="9">Table 1b. Demographic, clinical and genetic features of the Surveillance cohort.</td></tr><tr><td><italic>Males without recurrence</italic></td><td>59</td><td>30%</td><td>3 (5%)</td><td>8 (14%)</td><td>3 (5%)</td><td>10 (17%)</td><td>0 (0%)</td><td>8 (14%)</td></tr><tr><td><italic>Males with recurrence</italic></td><td>90</td><td>45%</td><td>45 (50%)</td><td>53 (59%)</td><td>20 (22%)</td><td>59 (66%)</td><td>20 (22%)</td><td>53 (59%)</td></tr><tr><td><italic>Females without recurrence</italic></td><td>17</td><td>9%</td><td>5 (29%)</td><td>3 (18%)</td><td>0 (0%)</td><td>6 (35%)</td><td>0 (0%)</td><td>6 (35%)</td></tr><tr><td><italic>Females with recurrence</italic></td><td>33</td><td>17%</td><td>15 (45%)</td><td>19 (58%)</td><td>11 (33%)</td><td>33 (100%)</td><td>6 (18%)</td><td>19 (58%)</td></tr><tr><td><italic>Original Tumor Diagnosis</italic></td><td/><td/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td><italic>PUNLMP</italic></td><td>12</td><td>4%</td><td>5 (42%)</td><td>2 (17%)</td><td>1 (8%)</td><td>6 (50%)</td><td>0 (0%)</td><td>2 (17%)</td></tr><tr><td><italic>CIS</italic></td><td>25</td><td>8%</td><td>11 (44%)</td><td>13 (52%)</td><td>6 (24%)</td><td>14 (56%)</td><td>5 (20%)</td><td>10 (40%)</td></tr><tr><td><italic>LGTCC</italic></td><td>107</td><td>35%</td><td>27 (25%)</td><td>34 (32%)</td><td>8 (7%)</td><td>41 (38%)</td><td>0 (0%)</td><td>59 (55%)</td></tr><tr><td><italic>HGTCC</italic></td><td>62</td><td>20%</td><td>22 (36%)</td><td>24 (39%)</td><td>10 (16%)</td><td>30 (49%)</td><td>4 (7%)</td><td>16 (26%)</td></tr><tr><td><italic>INTCC</italic></td><td>104</td><td>34%</td><td>39 (38%)</td><td>47 (45%)</td><td>29 (28%)</td><td>54 (52%)</td><td>20 (19%)</td><td>34 (33%)</td></tr><tr><td><italic>Original Tumor Stage</italic></td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td><italic>pTis</italic></td><td>25</td><td>8%</td><td>11 (44%)</td><td>13 (52%)</td><td>6 (24%)</td><td>14 (56%)</td><td>5 (20%)</td><td>10 (40%)</td></tr><tr><td><italic>pTa</italic></td><td>181</td><td>58%</td><td>54 (30%)</td><td>60 (33%)</td><td>19 (19%)</td><td>77 (43%)</td><td>4 (2%)</td><td>77 (43%)</td></tr><tr><td><italic>pT1</italic></td><td>71</td><td>23%</td><td>28 (39%)</td><td>35 (49%)</td><td>22 (31%)</td><td>39 (55%)</td><td>14 (20%)</td><td>23 (32%)</td></tr><tr><td><italic>pT2</italic></td><td>23</td><td>7%</td><td>9 (9%)</td><td>9 (39%)</td><td>7 (30%)</td><td>12 (52%)</td><td>5 (22%)</td><td>10 (43%)</td></tr><tr><td><italic>pT3</italic></td><td>9</td><td>3%</td><td>1 (11%)</td><td>2 (22%)</td><td>0</td><td>2 (22%)</td><td>1 (11%)</td><td>1 (11%)</td></tr><tr><td><italic>pT4</italic></td><td>1</td><td>0.3%</td><td>1 (100%)</td><td>1 (100%)</td><td>0</td><td>1 (100%)</td><td>N/A</td><td>N/A</td></tr><tr><td><italic>Routine cytology diagnosis*</italic></td><td/><td/><td/><td/><td/><td/><td valign="bottom"/><td valign="bottom"/></tr><tr><td><italic>Positive</italic></td><td>30</td><td>15%</td><td valign="bottom">21 (21%)</td><td>25 (83%)</td><td>20 (67%)</td><td>27 (90%)</td><td>N/A</td><td>N/A</td></tr><tr><td><italic>Atypical</italic></td><td>95</td><td>48%</td><td>38 (40%)</td><td>43 (45%)</td><td>18 (19%)</td><td>50 (53%)</td><td>N/A</td><td>N/A</td></tr><tr><td><italic>Negative</italic></td><td>71</td><td>36%</td><td>12 (17%)</td><td>13 (18%)</td><td>3 (4%)</td><td>19 (27%)</td><td>N/A</td><td>N/A</td></tr></tbody></table><table-wrap-foot><fn><p>*Cytology was available on only a subset of cases.</p><p>N/A Not Available.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-1-2"><title>Genetic analysis</title><p>We performed three separate tests for genetic abnormalities that might be found in urinary cells derived from BC (<xref ref-type="fig" rid="fig1">Figure 1</xref>). First, we evaluated mutations in selected regions of ten genes that have been shown to be frequently altered in urothelial tumors (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). For this purpose, we designed a specific set of primers that allowed us to detect mutations in as few as 0.03% of urinary cells (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). The capacity to detect such low-mutant fractions was a result of the incorporation of molecular barcodes in each of the primers, thereby substantially reducing the artifacts associated with massively parallel sequencing (<xref ref-type="bibr" rid="bib41">Kinde et al., 2011</xref>). Second, we evaluated <italic>TERT</italic> promoter mutations. A singleplex PCR was used for this analysis because the unusually high GC-content of the <italic>TERT</italic> promoter precluded its inclusion in the multiplex PCR design. Third, we evaluated the extent of aneuploidy using a technique in which a single PCR is used to co-amplify ~38,000 members of a subfamily of long interspersed nucleotide element-1 retrotransposons (L1 retrotransposons, also called LINEs). L1 retrotransposons, like other human repeats, have spread throughout the genome via retrotransposition and are found on all 39 non-acrocentric autosomal arms (<xref ref-type="bibr" rid="bib42">Kinde et al., 2012</xref>).</p><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.32143.005</object-id><label>Figure 3.</label><caption><title>Fraction of mutations found in the ten-gene panel in 231 urinary cell samples assessed in the BC early detection cohort, 56 urinary cell samples assessed in the UTUC cohort, and 132 urinary cell samples assessed in the BC surveillance cohort.</title></caption><graphic mime-subtype="png" mimetype="image" xlink:href="elife-32143-fig3-v2"/></fig><p>The multiplex assay detected mutations in 68% of the 175 urinary cell samples from the individuals who developed BC during the course of this study (95% CI, 61% to 75%) (<xref ref-type="table" rid="table1">Table 1a</xref> and <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). A total of 246 mutations were detected in eight of the ten target genes (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). The median mutant allele frequency (MAF) in the urinary cells with detectable mutations was 8% (8.14%. The most commonly altered genes were <italic>TP53</italic> (45% of the total mutations) and <italic>FGFR3</italic> (20% of the total mutations; <xref ref-type="fig" rid="fig3">Figure 3</xref>). The distribution of mutant genes was roughly consistent with expectations based on previous exome-wide sequencing studies of BCs (<xref ref-type="bibr" rid="bib7">Cancer Genome Atlas Research Network, 2014</xref>). At the thresholds used, 1.7% of the 395 patients in the early detection cohort who did not develop BC during the course of the study had a detectable mutation in any of the ten genes. At the same thresholds, none of the 188 urinary cell samples from healthy individuals had a mutation in any of the ten genes assayed (100% specificity, 95% CI, 98% to 100%).</p><p>Mutations in the <italic>TERT</italic> promoter were detected in 57% of the 175 urinary cell samples from the patients who developed cancer during the study interval (95% CI, 49% to 64%; <xref ref-type="table" rid="table1">Table 1a</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). The median <italic>TERT</italic> MAF in the urinary cells was 6% (5.76%). Mutations were detected in three positions; 98% of the mutations were at TERT:g.1295228 (79%) and TERT:g.1295250 (19%), which are 66 and 88 bp upstream of the transcription start site, respectively. The remaining 2% of mutations were found at TERT:g.1295242. The first two of these positions have been previously shown to be critical for the appropriate transcriptional regulation of <italic>TERT</italic>. In particular, the mutant alleles recruit the GABPA/B1 transcription factor, resulting in the H3K4me2/3 mark of active chromatin and reversing the epigenetic silencing present in normal cells (<xref ref-type="bibr" rid="bib83">Stern et al., 2015</xref>). Of the 395 patients in this cohort who did not develop BC during the course of the study, only 4% had a detectable mutation in the <italic>TERT</italic> promoter. Finally, only one of the 188 urinary samples from healthy individuals harbored a <italic>TERT</italic> promoter mutation.</p><p>Aneuploidy was detected in 46% (95% CI, 39% to 54%) of the 175 urinary cell samples from the patients who developed BC during the course of the study (<xref ref-type="table" rid="table1">Table 1a</xref> and <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). The most commonly altered chromosome arms were 5q, 8q, and 9p. These three chromosome arms harbor well-known oncogenes and tumor suppressor genes that have been shown to undergo copy number alterations in many cancers, including BC (<xref ref-type="bibr" rid="bib87">Vogelstein et al., 2013</xref>). Aneuploidy was detected in 1.5% of the urinary cell samples from the 395 patients who did not develop BC during the course of the study, but it was not detected in any of the 188 urinary samples from healthy individuals.</p></sec><sec id="s2-1-3"><title>Comparison with primary tumors</title><p>DNAs from resected or biopsied tumor samples from 102 of the patients enrolled in the BC early detection cohort were available for comparison and were examined with the same three assays used to probe the urinary cell samples. In 91 (89%) of these 102 cancers, at least one mutation in the eleven genes studied was present (in the 10-gene panel or the <italic>TERT</italic> promoter). Moreover, at least one of the mutations identified in the urine samples from these 102 patients was also identified in 83% of the corresponding primary BC samples (<xref ref-type="supplementary-material" rid="supp5">Supplementary files 5</xref> and <xref ref-type="supplementary-material" rid="supp6">6</xref>).</p><p>Analysis of these tumors also shed light on the basis for ‘false negatives,’ the urine samples with no detectable mutations from patients who ultimately developed BC. We attributed false negatives to the possibility that the corresponding BC either did not harbor a mutation in any of these 11 genes or the fraction of neoplastic cells in the urine sample was insufficient to allow detection with the assays used. We identified a mutation in at least one of the 11 genes in 62% of the primary tumors from patients with false negative urine tests (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> and <xref ref-type="supplementary-material" rid="supp8">8</xref>). We concluded that 62% of the 29 false negative tests were due to insufficient cancer cells in the urine while the remaining 38% were due to the absence of any of the queried mutations in the primary tumor tissue.</p></sec><sec id="s2-1-4"><title>UroSEEK: biomarkers in combination</title><p>The ten-gene multiplex assay, the <italic>TERT</italic> singleplex assay, and the aneuploidy assays yielded 68%, 57%, and 46% sensitivities, respectively, when used separately (<xref ref-type="table" rid="table1">Table 1a</xref> and <xref ref-type="supplementary-material" rid="supp5">Supplementary files 5</xref>, <xref ref-type="supplementary-material" rid="supp6">6,</xref> and <xref ref-type="supplementary-material" rid="supp7">7</xref>). Sensitivity was increased when the three assays were performed on each urine cell sample. In samples without <italic>TERT</italic> promoter mutations (<italic>n</italic> = 45), mutations in one of the other ten genes were detected (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Conversely, 35 samples negative for mutations in the multiplex assay were detected by virtue of <italic>TERT</italic> promoter mutations (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). Finally, ten of the urinary cell samples without any detectable mutations in the 11 genes were positive for aneuploidy (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). Thus, when the three assays were used together (test termed ‘UroSEEK’), and a positive result in any one of the assays was sufficient to score a sample as positive, the sensitivity rose to 83% (95% CI, 76% to 88%). Only one of the 188 samples from healthy individuals was scored positive by UroSEEK (specificity 99.5%, CI 97% to 100%). Twenty-six (6.5%) of the 395 patients in the BC early detection cohort who did not develop BC during the course of the study scored positive by the UroSEEK test (specificity 93%, CI 91% to 96%). On average, UroSEEK positivity preceded the diagnosis of BC by 2.3 months, and in eight cases, by &gt;one year (<xref ref-type="fig" rid="fig5">Figure 5</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.32143.006</object-id><label>Figure 4.</label><caption><title>Venn diagram showing the distribution of positive results for each of the three UroSEEK assays for the (A) BC early detection (B) UTUC and (C) BC surveillance cohorts.</title><p>URO = Ten gene panel, <italic>TERT</italic> = <italic>TERT</italic> promoter region, ANEU = Aneuploidy test.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-32143-fig4-v2"/></fig><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.32143.007</object-id><label>Figure 5.</label><caption><title>Bar graphs of the lead time between a positive UroSEEK test and the detection of disease at the clinical level in the (<bold>A</bold>) BC early detection and (<bold>B</bold>) BC surveillance cohorts.</title></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-32143-fig5-v2"/></fig></sec><sec id="s2-1-5"><title>UroSEEK plus cytology</title><p>As both cytology and UroSEEK are non-invasive tests and can be performed on the same urine sample, we assessed their performance in combination. Cytology was available for 347 patients in the BC early detection cohort (<xref ref-type="table" rid="table1">Table 1a</xref> and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Among the 40 patients who developed biopsy-proven cancer in this cohort, cytology was positive in 17 cases (43% sensitivity), and UroSEEK was positive in 100% of these cancer patients. UroSEEK was also positive in 95% of 23 cancer patients whose urines were negative by cytology. Thus, in combination, UroSEEK plus cytology achieved 95% (95% CI, 83% to 99%) sensitivity, a 12% increase over UroSEEK and a 52% increase over cytology. Finally, none of the 299 patients who did not develop cancer over the course of the study were positive by cytology (100% specificity), but 20 (6.6%) were positive by UroSEEK, giving the combination of UroSEEK and cytology a specificity of 93% (95% CI, 90% to 96%).</p></sec></sec><sec id="s2-2"><title>UTUC cohort</title><sec id="s2-2-1"><title>Cohort characteristics</title><p>The gender distribution of this cohort, 32 females and 24 males, is atypical of UTUC patients in Western countries where males predominate (<xref ref-type="bibr" rid="bib77">Shariat et al., 2011</xref>), but is consistent with earlier epidemiologic studies of Taiwanese individuals with known exposures to AA (summary in <xref ref-type="table" rid="table2">Table 2</xref>; individual data in <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>)(<xref ref-type="bibr" rid="bib9">Chen et al., 2012</xref>). Tobacco use was reported by 18% in this cohort and were all males. Based on estimated glomerular filtration rate (eGFR) values, renal function was unimpaired (chronic kidney disease (CKD) stage 0–2) in 45% of the subjects, while mild-to-moderate renal disease (CKD stage 3) or severe disease (CKD stages 4–5) was noted for 43% and 12% of the cohort, respectively (<xref ref-type="table" rid="table2">Table 2</xref>). Tumors were confined to a single site along the upper urinary tract in the majority of cases (38% renal pelvis; 39% ureter), while multifocal tumors affecting both renal pelvis and ureter occurred in 23% of the patients. Synchronous bladder cancer (diagnosed within 3 months prior to nephroureterectomy) was present in 38% of patients. Tumors were classified as high grade in 89% of the cases, with the majority categorized as muscle-invasive (T2-T4, 66%; <xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="table2" position="float"><object-id pub-id-type="doi">10.7554/eLife.32143.008</object-id><label>Table 2.</label><caption><title>Demographic, clinical and genetic features of the UTUC cohort stratified by UroSEEK results.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th>N</th><th>%</th><th>Ten-gene multiplex positive</th><th>TERT positive</th><th>Aneuploidy positive</th><th>UroSEEK positive</th></tr></thead><tbody><tr><td><bold>All subjects</bold></td><td>56</td><td>100%</td><td>64%</td><td>29%</td><td>39%</td><td>75%</td></tr><tr><td valign="bottom"><bold>Gender</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom"> Males</td><td>24</td><td>43%</td><td>71%</td><td>33%</td><td>54%</td><td>83%</td></tr><tr><td valign="bottom"> Females</td><td>32</td><td>57%</td><td>59%</td><td>25%</td><td>28%</td><td>69%</td></tr><tr><td valign="bottom"><bold>CKD stage</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom"> 0–2</td><td>25</td><td>45%</td><td>68%</td><td>36%</td><td>44%</td><td>76%</td></tr><tr><td valign="bottom"> 3A</td><td>14</td><td>25%</td><td>50%</td><td>21%</td><td>43%</td><td>71%</td></tr><tr><td valign="bottom"> 3B</td><td>10</td><td>18%</td><td>80%</td><td>20%</td><td>40%</td><td>80%</td></tr><tr><td valign="bottom"> 4</td><td>4</td><td>7%</td><td>25%</td><td>50%</td><td>0%</td><td>50%</td></tr><tr><td valign="bottom"> 5</td><td>3</td><td>5%</td><td>100%</td><td>0%</td><td>33%</td><td>100%</td></tr><tr><td valign="bottom"><bold>Tumor grade</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom"> Low</td><td valign="bottom">6</td><td valign="bottom">11%</td><td>67%</td><td>50%</td><td>17%</td><td>67%</td></tr><tr><td valign="bottom"> High</td><td valign="bottom">50</td><td valign="bottom">89%</td><td>64%</td><td>26%</td><td>42%</td><td>76%</td></tr><tr><td valign="bottom"><bold>Tumor stage</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom"> Ta</td><td valign="bottom">11</td><td valign="bottom">20%</td><td>73%</td><td>55%</td><td>45%</td><td>82%</td></tr><tr><td valign="bottom"> T1</td><td valign="bottom">8</td><td valign="bottom">14%</td><td>50%</td><td>0%</td><td>38%</td><td>75%</td></tr><tr><td valign="bottom"> T2</td><td valign="bottom">10</td><td valign="bottom">18%</td><td>80%</td><td>20%</td><td>10%</td><td>80%</td></tr><tr><td valign="bottom"> T3</td><td valign="bottom">24</td><td valign="bottom">43%</td><td>67%</td><td>33%</td><td>54%</td><td>79%</td></tr><tr><td valign="bottom"> T4</td><td valign="bottom">3</td><td valign="bottom">5%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td valign="bottom"><bold>Upper urinary tract tumor site</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom"> Lower ureter</td><td valign="bottom">17</td><td valign="bottom">30%</td><td>76%</td><td>18%</td><td>35%</td><td>76%</td></tr><tr><td valign="bottom"> Upper ureter</td><td valign="bottom">1</td><td valign="bottom">2%</td><td>100%</td><td>0%</td><td>0%</td><td>100%</td></tr><tr><td valign="bottom"> Ureterovesical junction</td><td valign="bottom">2</td><td valign="bottom">4%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></tr><tr><td valign="bottom"> Lower ureter and upper ureter</td><td valign="bottom">2</td><td valign="bottom">4%</td><td>100%</td><td>50%</td><td>50%</td><td>100%</td></tr><tr><td valign="bottom"> Renal pelvis</td><td valign="bottom">21</td><td valign="bottom">38%</td><td>57%</td><td>38%</td><td>38%</td><td>76%</td></tr><tr><td valign="bottom"> Renal pelvis and lower ureter</td><td valign="bottom">4</td><td valign="bottom">7%</td><td>75%</td><td>25%</td><td>50%</td><td>100%</td></tr><tr><td valign="bottom"> Renal pelvis and upper ureter</td><td valign="bottom">5</td><td valign="bottom">9%</td><td>40%</td><td>40%</td><td>60%</td><td>60%</td></tr><tr><td valign="bottom"> Renal pelvis, lower ureter, upper ureter</td><td valign="bottom">4</td><td valign="bottom">7%</td><td>75%</td><td>25%</td><td>50%</td><td>75%</td></tr><tr><td valign="bottom"><bold>Synchronous bladder cancer</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom"> Present</td><td valign="bottom">21</td><td valign="bottom">38%</td><td>52%</td><td>29%</td><td>33%</td><td>62%</td></tr><tr><td valign="bottom"> Absent</td><td>35</td><td>63%</td><td>71%</td><td>29%</td><td>43%</td><td>83%</td></tr><tr><td valign="bottom"><bold>UTUC risk factors</bold></td><td/><td/><td/><td/><td/><td/></tr><tr><td valign="bottom"> Aristolactam-DNA adducts present</td><td valign="bottom">54</td><td valign="bottom">96%</td><td>65%</td><td>30%</td><td>39%</td><td>74%</td></tr><tr><td valign="bottom"> Smoking history</td><td valign="bottom">10</td><td valign="bottom">18%</td><td>70%</td><td>30%</td><td>60%</td><td>70%</td></tr><tr><td valign="bottom"> CKD, chronic kidney disease.</td><td valign="bottom"/><td valign="bottom"/><td/><td/><td/><td/></tr></tbody></table></table-wrap></sec><sec id="s2-2-2"><title>Genetic analysis</title><p>The multiplex assay detected at least one mutation in 36 of the 56 urinary cell samples from UTUC patients (64%, 95% CI, 51% to 76%; <xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref>). A total of 57 mutations were detected in nine of the ten target genes (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The median MAF in the urinary cells was 5.6% and ranged from 0.3% to 80%. The most commonly altered genes were <italic>TP53</italic> (n = 33, 58% of the 57 mutations) and <italic>FGFR3</italic> (n = 9, 16% of the 57 mutations; <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>Mutations in the <italic>TERT</italic> promoter were detected in 16 of the 56 urinary cell samples from UTUC patients (29%, 95% CI, 18% to 42%; <xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="supplementary-material" rid="supp11">Supplementary file 11</xref>). The median <italic>TERT</italic> MAF in the urinary cells was 2.22% and ranged from 0.59% to 46.3%. One of the 188 urinary samples from healthy individuals harbored a mutation (<italic>TERT</italic> g.1295250C &gt; T with a MAF of 0.39%). In the UTUC urinary cell samples, most of the TERT mutations (94%) were at one of two positions, TERT:g.1295228 (67%) and TERT:g.1295250 (28%), which are 66 and 88 bp upstream of the transcription start site, respectively. A third position, TERT:g.1295242, was also involved in the remaining 6% of cases.</p><p>Aneuploidy was detected in 22 of the 56 urinary cell samples from UTUC patients (39%, 95% CI, 28% to 52%, <xref ref-type="supplementary-material" rid="supp12">Supplementary file 12</xref> and <xref ref-type="supplementary-material" rid="supp13">13</xref>). The most commonly altered chromosome arms were 1q, 7q, 8q, 17 p, and 18q.</p></sec><sec id="s2-2-3"><title>Comparison with primary tumors</title><p>The distribution of mutant genes in primary tumors (<xref ref-type="supplementary-material" rid="supp14">Supplementary file 14</xref>) was consistent with findings from some (<xref ref-type="bibr" rid="bib29">Hoang et al., 2013</xref>; <xref ref-type="bibr" rid="bib46">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib96">Yuan et al., 2016</xref>) but not all (<xref ref-type="bibr" rid="bib57">Moss et al., 2017</xref>; <xref ref-type="bibr" rid="bib76">Sfakianos et al., 2015</xref>), exome-wide and targeted sequencing studies of UTUCs. In the present study, <italic>TP53</italic> mutations were found only in high-grade UTUCs, while <italic>FGFR3</italic> mutations dominated in low-grade tumors (present in 5/6). Such mutational patterns have been previously reported by others (<xref ref-type="bibr" rid="bib76">Sfakianos et al., 2015</xref>). However, the overall frequency of <italic>FGFR3</italic> mutations in our UTUC cohort (21%) was relatively low compared to values reported by <xref ref-type="bibr" rid="bib57">Moss et al. (2017)</xref> (74%) and <xref ref-type="bibr" rid="bib76">Sfakianos et al. (2015)</xref> (54%), but was comparable to values reported by <xref ref-type="bibr" rid="bib29">Hoang et al., 2013</xref> (8%) and <xref ref-type="bibr" rid="bib46">Lee et al. (2018)</xref> (13%). We attribute this difference to the race/ethnicity profile of the cohorts under comparison, as <italic>FGFR3</italic> mutation levels are relatively low in UTUCs from Han Chinese patients (3–9%) compared to Western patients (36–60%), as reported by <xref ref-type="bibr" rid="bib96">Yuan et al. (2016)</xref>. Our cohort was Taiwanese and principally of Han Chinese descent, as were the <xref ref-type="bibr" rid="bib29">Hoang et al., 2013</xref> (Taiwanese) and <xref ref-type="bibr" rid="bib46">Lee et al. (2018)</xref> (Korean) cohorts, whereas Western patients were examined in the <xref ref-type="bibr" rid="bib76">Sfakianos et al. (2015)</xref> and <xref ref-type="bibr" rid="bib57">Moss et al. (2017)</xref> studies.</p><p>Tumor samples from all 56 patients with UTUC were available for comparison and were subjected to the same three assays used to analyze the urinary cell samples. At least one mutation could be identified in the urinary cells from 39 UTUC cases. In 35 (90%) of these 39 cases, at least one of the mutations identified in the urine sample (<xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref> and <xref ref-type="supplementary-material" rid="supp11">11</xref>) was also identified in the corresponding tumor DNA sample (<xref ref-type="supplementary-material" rid="supp14">Supplementary file 14</xref> and <xref ref-type="supplementary-material" rid="supp15">15</xref>). When all 80 mutations identified in the urinary cells were considered, 63 (79%) were identified in the corresponding tumor sample. The discrepancies between urine and tumor samples in any of the three assays might be explained by the fact that we had access to only one tumor per patient, even though more than one anatomically distinct tumor was often evident clinically (<xref ref-type="table" rid="table2">Table 2</xref>). In addition, DNA was extracted from only one location in each tumor; thus, intratumoral heterogeneity (<xref ref-type="bibr" rid="bib52">McGranahan et al., 2015</xref>) could have been responsible for some of the discrepancies.</p><p>The tumor data also helped to establish why 17 of the 56 urinary cell samples from UTUC patients did not contain detectable mutations. From the evaluation of the primary tumor samples, we found that only four (24%) of these 17 urine samples were from patients whose tumors did not contain any of the queried mutations (<xref ref-type="supplementary-material" rid="supp14">Supplementary file 14</xref> and <xref ref-type="supplementary-material" rid="supp15">15</xref>). Thus, we concluded that the main reason for failure of the mutation test was an insufficient number of cancer cells in the urine, which accounted for 13 (76%) of the 17 failures.</p><p>Aneuploidy was observed in 22 of the urinary cell samples (<xref ref-type="supplementary-material" rid="supp12">Supplementary file 12</xref>). Overall, 96% of the chromosomal gains or losses observed in the urinary cells were also observed in the primary tumors (<xref ref-type="supplementary-material" rid="supp13">Supplementary file 13</xref>). Conversely, aneuploidy was not observed in 34 of the urinary cell samples. Evaluation of the corresponding 56 tumors with the same assay demonstrated that all but three were aneuploid. Therefore, as with mutations, the main reason for failure of the aneuploidy assay was insufficient neoplastic DNA in the urinary cells.</p></sec><sec id="s2-2-4"><title>UroSEEK: biomarkers in combination</title><p>The ten-gene multiplex assay, the <italic>TERT</italic> singleplex assay, and the aneuploidy assays yielded 64%, 29%, and 39% sensitivities, respectively, when used separately in the UTUC cohort (<xref ref-type="table" rid="table2">Table 2</xref>). Mutations in one of the other ten genes were detected in 23 samples without TERT promoter mutations (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Conversely, three samples without detectable mutations in the multiplex assay scored positive for <italic>TERT</italic> promoter mutations (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Furthermore, three of the urinary cell samples without any detectable mutations were positive for aneuploidy (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Thus, when the three assays were used together, and a positive result in any one assay was sufficient to score a sample as positive, the sensitivity rose to 75% (95% CI 62.2% to 84.6%).</p><p>To determine the basis for the increased sensitivity afforded by the combination assays, we evaluated data from the primary tumors of the three patients whose urinary cell samples exhibited aneuploidy but did not harbor detectable mutations. We found that these three tumors did not contain any mutations in the 11 queried genes, which explained why these same assays were negative when applied to the urinary cell DNAs. These three tumors were aneuploid, thus enabling their detection through copy number variations in the urinary cell samples.</p></sec><sec id="s2-2-5"><title>Correlation with clinical features</title><p>The most clinically desirable biomarkers are those associated with early stage tumor development as they enable surgical removal of lesions before widespread metastasis. In UTUC, ten-year cancer specific survival rates show that 91% of patients with stage T1 malignancies are expected to be cured by surgery, compared to only 78%, 34% and 0% of patients with stage T2, T3, or T4 tumors, respectively (<xref ref-type="bibr" rid="bib49">Li et al., 2008</xref>). In our cohort, UroSEEK was equally sensitive for detecting early and late UTUCs. The test was positive in 15 (79%) of 19 patients with stage Ta/T1 tumors and 27 (73%) of 37 patients with stage T2-T4 tumors (<xref ref-type="table" rid="table2">Table 2</xref>). Sensitivity was comparable across gender, tumor grade, tumor location and risk factors for developing UTUC (<xref ref-type="table" rid="table2">Table 2</xref>), indicating that the assay was suitable for evaluation of diverse patient populations. UroSEEK performance was also comparable in UTUC cohorts with and without synchronous BC (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>UroSEEK was also considerably more sensitive than urine cytology in the UTUC cohort (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig6">6</xref>). Cytology was available in 42 cases, and of these, four (9.5%) were positive on cytology. UroSEEK detected all four of these cases. In addition, UroSEEK was positive in 5/7 cases that had an equivocal cytology diagnosis of suspicious for malignancy, and 22/31 samples that were negative on cytology.</p><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.32143.009</object-id><label>Figure 6.</label><caption><title>Bar graphs representing the performance of Cytology vs. UroSEEK in diagnosis of low- and high-grade urothelial neoplasms in the early detection and surveillance BC cohorts and the UTUC cohort.</title></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-32143-fig6-v2"/></fig></sec><sec id="s2-2-6"><title>Aristolochic acid exposure</title><p>The activated metabolites of AA bind covalently to the exocyclic amino groups in purine bases, with a preference for dA, leading to characteristic A &gt; T transversions (<xref ref-type="bibr" rid="bib30">Hollstein et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Moriya et al., 2011</xref>). To determine whether individuals in the UTUC cohort had been exposed to AA, we quantified renal cortical DNA adducts using mass spectrometry (<xref ref-type="bibr" rid="bib97">Yun et al., 2012</xref>). All but two of the 56 patients had detectable aristolactam (AL)-DNA adducts (<xref ref-type="table" rid="table2">Table 2</xref>) with levels ranging from 0.4 to 68 dA-AL-I adducts per 10<sup>8</sup> nucleotides. Moreover, the A &gt; T signature mutation (<xref ref-type="bibr" rid="bib29">Hoang et al., 2013</xref>) associated with AA was highly represented in the mutational spectra of <italic>TP53</italic> (18/32 A &gt; T) and <italic>HRAS</italic> (2/2 A &gt; T) found in urinary cells (<xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref>).</p></sec></sec><sec id="s2-3"><title>BC surveillance cohort</title><sec id="s2-3-1"><title>Cohort characteristics</title><p>Our strategy for BC surveillance was different than for early detection of BC. In these patients, a BC was surgically excised for treatment and diagnosis. Tumor tissue was thus generally available, and in most such tumors, a mutation was identified. For example, we found during the course of this study that a mutation in at least one of the 11 queried genes was present in 95.2% of BCs evaluated. We evaluated a total of 322 patients with a BC tumor containing a mutation in at least one of the 11 genes and a urine sample collected within 0–5 years after surgery. We determined whether a single urine sample taken a relatively short time following surgical excision of the BC could reveal residual disease in these 322 patients, as evidenced by later recurrence. In 187 (58%) of the 322 patients, clinically evident BC developed after a median follow-up period of 10.7 months (range 0 to 51 months). The histopathologic types and tumor stages of these patients are summarized in <xref ref-type="table" rid="table1">Table 1b</xref> and detailed in <xref ref-type="supplementary-material" rid="supp16">Supplementary file 16</xref>. The median age of the participants was 62 years (range 20 to 93), and 75% of the patients were male as expected from the demographics of BC.</p></sec><sec id="s2-3-2"><title>Genetic analysis</title><p>The multiplex assay detected mutations in 52% of the urinary cell samples from patients who developed recurrent BC during the study interval (95% CI, 45% to 60%; <xref ref-type="supplementary-material" rid="supp16">Supplementary file 16</xref> and <xref ref-type="supplementary-material" rid="supp17">Supplementary file 17</xref>). The median MAF in the urinary cells with detectable mutations was 7% (6.89%). The most commonly altered genes were <italic>FGFR3</italic> (43% of the 134 mutations) and <italic>TP53</italic> (30% of the 134 mutations; <xref ref-type="fig" rid="fig3">Figure 3</xref>). Some cases were however considered to be false positives; 7% of the 135 patients who did not develop recurrent BC during the course of the study had a detectable mutation in their urinary cell sample (see Discussion). The mean interval between a positive multiplex assay test and the diagnosis of recurrent BC was 7 months (range 0 to 51 months).</p><p>Mutations in the <italic>TERT</italic> promoter were detected in 57% of the urinary cell samples from patients who developed recurrent BC during the study interval (95% CI 44% to 58%; (<xref ref-type="table" rid="table1">Table 1b</xref> and <xref ref-type="supplementary-material" rid="supp18">Supplementary file 18</xref>). The median <italic>TERT</italic> MAF in the urinary cells with detectable mutations was 5% (5.02%). Mutations were detected in the same three promoter positions observed in the urinary cells of the early detection cohort. The mean interval between a positive <italic>TERT</italic> test and the diagnosis of recurrent BC was 7 months (range 0 to 40 months). Some results were considered to be false positives; 10% (95% CI, 83% to 94%) of the 135 patients who did not develop recurrent BC during the course of the study had a detectable <italic>TERT</italic> promoter mutation in their urine sample.</p><p>Aneuploidy was detected in 28% (95% CI 24% to 37%) of the urinary cell samples from the patients who developed recurrent BC during the course of the study (<xref ref-type="table" rid="table1">Table 1b</xref> and <xref ref-type="supplementary-material" rid="supp19">Supplementary file 19</xref>). The most commonly altered chromosome arms were 8 p, 8q, and 9 p, as in the early detection cohort. In this assay, only 2% of the 135 patients who did not develop recurrent BC during the course of the study exhibited aneuploidy in at least one of their urinary cell samples.</p></sec><sec id="s2-3-3"><title>UroSEEK: biomarkers in combination</title><p>The ten-gene multiplex assay, the <italic>TERT</italic> singleplex assay, and the aneuploidy assays yielded 52%, 57%, and 28% sensitivities, respectively, when used separately on the BC surveillance cohort (<xref ref-type="table" rid="table1">Table 1b</xref> and <xref ref-type="supplementary-material" rid="supp17">Supplementary file 17</xref>, <xref ref-type="supplementary-material" rid="supp18">18</xref> and <xref ref-type="supplementary-material" rid="supp19">19</xref>). Thirty-two samples without <italic>TERT</italic> promoter mutations were detected by mutations in one of the other ten genes (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="supplementary-material" rid="supp17">Supplementary file 17</xref>). Conversely, 41 samples without detectable mutations in the multiplex assay had <italic>TERT</italic> promoter mutations. Finally, aneuploidy was detected in three of the urinary cell samples without mutations in any of the 11 genes. Thus, the sensitivity of UroSEEK was 68% (95% CI, 59% to 73%; <xref ref-type="table" rid="table1">Table 1b</xref>). Twenty percent of the 135 patients in this cohort who did not develop BC during the course of the study scored positive by the UroSEEK test, yielding a specificity of 80% (95% CI, 77% to 91%). On average, UroSEEK positivity preceded the diagnosis of BC by 7 months, and in 47 cases, by &gt;one year (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="supplementary-material" rid="supp16">Supplementary file 16</xref>).</p><p>Cytology was available for 196 patients in the BC surveillance cohort (<xref ref-type="supplementary-material" rid="supp16">Supplementary file 16</xref>). Among the 120 patients who developed recurrent BC in this cohort, 30 (25%) were positive by cytology. Conversely, no positive cytology results were observed in patients without recurrent tumors. UroSEEK was positive in 90% of the recurrent BC patients with urines positive by cytology and in 61% of the 90 recurrent BC patients with urines negative by cytology. Thus, in combination, UroSEEK plus cytology achieved 71% sensitivity (95% CI, 61.84% to 78.77; <xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="supplementary-material" rid="supp17">Supplementary files 17</xref>, <xref ref-type="supplementary-material" rid="supp18">18</xref>, <xref ref-type="supplementary-material" rid="supp19">19</xref>). Among the 76 patients with cytology who did not develop recurrent BC during the course of the study, 18% scored as positive by either cytology or UroSEEK, which yielded a specificity of 82% (95% CI, 71% to 90%; see Discussion).</p></sec></sec><sec id="s2-4"><title>Low- vs. high-grade urothelial neoplasms (both BC cohorts)</title><p>The advantage of UroSEEK over cytology was particularly evident in low-grade BC (Papillary urothelial neoplasms of low malignant potential and non-invasive low-grade papillary urothelial carcinomas). Cytology was available for 49 low-grade tumors evaluated in this study (six from the early detection cohort and 43 from the Surveillance cohort). None of these low-grade tumors, however, were detected by cytology (0% sensitivity; 95% CI, 0.0% to 6.7%). In contrast, UroSEEK detected 67% (95% CI 51% to 81%) of the low-grade tumors (identical rate of 67% in both cohorts; <xref ref-type="supplementary-material" rid="supp20">Supplementary file 20</xref> and <xref ref-type="fig" rid="fig6">Figure 6</xref>). Cytology was also available for 102 high-grade tumors (in situ urothelial carcinoma, non-invasive high-grade papillary urothelial carcinoma or infiltrating high-grade urothelial carcinoma) evaluated in this study (early detection cohort, <italic>n</italic> = 34, and BC Surveillance cohort, <italic>n</italic> = 68). Cytology was positive in 45% of these patients (50% and 41% in the early detection and BC surveillance cohorts, respectively) while UroSEEK was positive in 80% (100% and 71% in the early detection and surveillance cohorts, respectively; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> and <xref ref-type="supplementary-material" rid="supp16">16</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Cytology is a non-invasive test that is highly specific, and in expert hands nearly always indicates the presence of urothelial malignancy when positive. This specificity was verified in our study: all 51 patients in the BC early detection cohort whose urine samples were positive by cytology developed biopsy-proven BC. However, cytology is not particularly sensitive. UroSEEK adds considerably to sensitivity, as it raised the sensitivity of cytology from 43% to 95% in the BC early detection cohort, from 25% to 71% in the BC Surveillance cohort, and from 10% to 75% in the UTUC cohort. The increased sensitivity was further highlighted by the fact that UroSEEK-positive results preceded clinical diagnosis or positive cytology by months to years in the BC surveillance cohort.</p><p>The advantage of using UroSEEK in addition to cytology was particularly evident for low-grade tumors. Cytology was negative in all 49 cases in the BC early detection cohort, while 2/3 of these patients were positive with UroSEEK. Similarly, UroSEEK correctly identified 80% of low-grade UTUC while none were detected by cytology. Another example of the utility of the combination of UroSEEK plus cytology was evident in patients with an equivocal cytology reading. A relatively large number of urine samples receive such an equivocal cytologic reading, even in the hands of a sub-specialized, board-certified cytopathology expert such as employed in the current study (<xref ref-type="bibr" rid="bib4">Barkan et al., 2016</xref>). In the BC early detection cohort, for example, 105 urine samples were scored as ‘atypical’, and of these cases, 19% developed recurrence while the other 81% did not. UroSEEK was positive in 95% of the atypical cases that developed BC, but only in 13% of the atypical cases that did not develop cancer. These results demonstrate that UroSEEK can be used to more confidently interpret atypical cytology results.</p><p>Although UroSEEK is more sensitive than cytology, it is less specific. In this study, we assessed specificity in several independent ways. The first, and in some ways, most straightforward, was in a collection of urine samples from healthy individuals. In these 188 individuals, only one sample was positive, yielding a specificity of 99.5% (CI 97% to 100%). Such high specificity can be considered the technical specificity of the test, but biological specificities are also important. In the BC early detection cohort, 26 of the 395 patients who did not develop BC scored positive, yielding a specificity of 93% (CI 90.50% to 96%), or a false positive rate of 6.5%. These ‘false positives’ detected by UroSEEK could result from several factors. First, we cannot be certain that the patients whose urinary cells harbored genetic alterations did not have cancer. The follow-up period for many of patients was only one year, and cystoscopy was not generally performed. Second, it is possible that there are clonal proliferations in the bladder epithelium that increase with age. The patients in the BC early detection cohort were on average older than the 188 healthy individuals used as controls (40 years vs. 58 years). Although this explanation is speculative, clonal proliferations that are not considered neoplastic have been described in the bone, skin, and other tissues (<xref ref-type="bibr" rid="bib67">Risques and Kennedy, 2018</xref>). Clonal proliferations may also be the basis for any discordance between mutations in urinary cells and in the primary tumors of the same patients. Although in the majority of cases, at least one of the mutations identified in the urine was also present in the primary tumor, this was not true in 22% of the cases in the BC early detection cohort. In these cases, UroSEEK could be detecting clonal proliferations in the bladder epithelium that did not progress to cancer, and such proliferations may be more common in patients with BC than in the general population <xref ref-type="bibr" rid="bib67">Risques and Kennedy, 2018</xref>Because only one biopsy from the primary tumor was available for comparison, it is also possible that intratumoral heterogeneity explains some of the discrepancies. False positives in the BC surveillance cohort could be explained in similar ways. False positives are not unique to our study; they have been observed in all other molecular assays for BC, including FDA-approved tests (<xref ref-type="bibr" rid="bib15">Dimashkieh et al., 2013</xref>; <xref ref-type="bibr" rid="bib23">Gopalakrishna et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">Hajdinjak, 2008</xref>). Whether the false positives in these other assays have the same biological basis is an important area for future research.</p><p>There are two factors that limit sensitivity for genetically-based biomarkers. First, a sample can only be scored as positive for the biomarker if it contains DNA from a sufficient number of neoplastic cells to be detected by the assay. Second, the tumor from which the neoplastic cells were derived must harbor the genetic alteration that is queried. Combination assays can increase sensitivity by assessing more genetic alterations, and are thereby more likely to detect at least one genetic alteration present in the tumor. However, mutations in clinical samples are often present at low allele frequencies (<xref ref-type="supplementary-material" rid="supp5">Supplementary files 5</xref>, <xref ref-type="supplementary-material" rid="supp6">6</xref>, <xref ref-type="supplementary-material" rid="supp10">10</xref> and <xref ref-type="supplementary-material" rid="supp11">11</xref>), requiring high coverage of every base queried. It would be prohibitively expensive to perform whole exome sequencing at 10,000x coverage, for example, so some compromise is needed. In our study, we evaluated carefully selected regions of 11 genes, including TERT, together with copy number analysis of 39 chromosome arms. Even if a tumor does not contain a genetic alteration in one of the 11 genes assessed, it might still be detectable by the urinary cell assay for aneuploidy. The sensitivity of aneuploidy detection however is less than that of the mutation assays. Simulations demonstrated that DNA containing a minimum of 1% neoplastic cells is required for reliable aneuploidy detection, while mutations present in as few as 0.03% of the DNA templates can be detected by the mutation assays used in our study (<xref ref-type="bibr" rid="bib5">Bettegowda et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Kinde et al., 2013</xref>; <xref ref-type="bibr" rid="bib91">Wang et al., 2016</xref>). Nevertheless, urinary cell samples that had relatively high fractions of neoplastic cells but did not contain a detectable mutation in the 11 queried genes should still be detectable due to their aneuploidy. In addition, some of the mutations in the 11 genes queried, such as large insertions or deletions or complex changes, might be undetectable by mutation-based assays, but such samples might still score positive in a test for aneuploidy.</p><p>For UTUC, although the approach described here has significant potential for screening purposes, we emphasize that the current study demonstrates proof-of-principle rather than clinical applicability given the small number of patients evaluated. Another caveat is that our assays cannot distinguish between UTUC and BC. We consider this a strength of the assay since the detection of BC is equally important given that patients exposed to AA are at risk for BC as well as for UTUC (<xref ref-type="bibr" rid="bib65">Poon et al., 2015</xref>). It has been estimated that 100 million people in China are at risk for UTUC as a result of exposure to this carcinogen (<xref ref-type="bibr" rid="bib26">Grollman, 2013</xref>; <xref ref-type="bibr" rid="bib33">Hu et al., 2004</xref>). Non-invasive, sensitive methods to screen the large numbers of at-risk individuals for UTUC in such populations are thus clearly desirable. UroSEEK could also be used to monitor for UTUC recurrence in bladder, which occurs in 22% to 47% of cases, or in the contralateral tract affecting 2% to 6% of patients (<xref ref-type="bibr" rid="bib69">Rouprêt et al., 2015</xref>) and up to 30% of AA-related UTUC patients (<xref ref-type="bibr" rid="bib10">Chen et al., 2013</xref>). Currently, no such screening methods are available, as illustrated in the current study where urine cytology failed to detect 90% of UTUC cases. Radiologic tests, such as MRI or CT-scans, are not well suited for screening, and the latter confers significant radiation exposure. Ureteroscopy is often definitive, but in addition to being invasive, requires highly skilled clinicians and is also ill-suited as a screening tool (<xref ref-type="bibr" rid="bib21">Golan et al., 2015</xref>).</p><p>Liquid biopsy has recently gained attention as a non-invasive approach to screen for cancer. Although this concept often refers to blood samples, it can be applied to other body fluids, such as urine (<xref ref-type="bibr" rid="bib64">Patel et al., 2017</xref>; <xref ref-type="bibr" rid="bib78">Sidransky et al., 1991</xref>; <xref ref-type="bibr" rid="bib85">Togneri et al., 2016</xref>). Urine contains DNA from several sources, including (i) glomerular filtration of circulating free DNA (<xref ref-type="bibr" rid="bib6">Botezatu et al., 2000</xref>) released by normal and tumor cells from sites throughout the body; (ii) DNA released directly into urine by normal and tumor cells of the urinary tract; and (iii) intact normal or malignant cells of the urinary tract exfoliated into urine (<xref ref-type="bibr" rid="bib5">Bettegowda et al., 2014</xref>; <xref ref-type="bibr" rid="bib14">Dawson et al., 2013</xref>; <xref ref-type="bibr" rid="bib17">Dressman et al., 2003</xref>; <xref ref-type="bibr" rid="bib19">Forshew et al., 2012</xref>; <xref ref-type="bibr" rid="bib27">Haber and Velculescu, 2014</xref>; <xref ref-type="bibr" rid="bib43">Kinde et al., 2013</xref>; <xref ref-type="bibr" rid="bib82">Springer et al., 2015</xref>; <xref ref-type="bibr" rid="bib86">Vogelstein and Kinzler, 1999</xref>; <xref ref-type="bibr" rid="bib89">Wang et al., 2015a</xref>; <xref ref-type="bibr" rid="bib90">Wang et al., 2015b</xref>; <xref ref-type="bibr" rid="bib91">Wang et al., 2016</xref>). We chose the latter option for the current study to increase sensitivity and specificity.</p><p>While optimizing conditions for the current study, we compared the relative performance of mutation assays in matched plasma and urine samples obtained from 14 UTUC patients. In each case, a <italic>TERT</italic> or <italic>TP53</italic> mutation was first identified in the primary tumor. That particular mutation was subsequently queried in DNA from the urine and plasma using a singleplex assay. Mutations were detected in 93% (13/14) of the urinary cell DNA samples compared to 36% (5/14) of the plasma samples. Importantly, the plasma test failed to identify any of the six non-muscle-invasive cancers (Ta/T1), while all six (100%) were identified in the matched urinary cell DNA samples. The superior performance in urinary cells was likely due to a substantial enrichment for mutated DNA in these cells compared to plasma; the median MAF in plasma when a mutation was detectable was only 0.3% compared to 15% in the urinary cells.</p><p>Our study lays the conceptual and practical framework for a novel test that could be used in the management of patients with urothelial cancer. Large prospective trials will be required to demonstrate the ability of UroSEEK to improve the management of patients with hematuria or dysuria or patients at risk for urothelial cancer recurrence. Before carrying out large-scale trials to evaluate such clinical utility, it is informative to predict what the performance characteristics of such a test might be. As one example, consider the use of UroSEEK plus cytology in patients presenting to their physician with microscopic hematuria or dysuria, a commonly encountered situation. In large population-based studies involving over 80,000 individuals participating in health screening, the fraction of individuals with micro-hematuria ranged from 2.4% to 31.1% (<xref ref-type="bibr" rid="bib13">Davis et al., 2012</xref>; <xref ref-type="bibr" rid="bib92">Wein et al., 2012</xref>). It has been estimated that 5% of such patients actually have urothelial cancer (<xref ref-type="bibr" rid="bib39">Khadra et al., 2000</xref>). In the current study, UroSEEK plus cytology had a sensitivity of 95% and a specificity of 93% for BC in patients with this presentation. These results extrapolate to a positive predictive value (PPV) of 66% (95% CI, 55% to 74%) and a negative predictive value (NPV) of 99.3% (95% CI, 97.3% to 99.8%). These values are well above those generally considered to be diagnostically helpful and are considerably higher than achieved in FDA-approved tests for this indication (<xref ref-type="bibr" rid="bib15">Dimashkieh et al., 2013</xref>; <xref ref-type="bibr" rid="bib28">Hajdinjak, 2008</xref>).</p><p>We envision that the first application of UroSEEK would be patients such as those described here in the cohorts used for early detection of BC and UTUC. Patients with hematuria who might otherwise be referred to cystoscopy would be tested by UroSEEK plus cytology. Such tests could be ordered by general practitioners and do not require consultation with a urologist. Only if a test was positive would cystoscopy be required. The sensitivities, specificities, and PPV and NPV of UroSEEK plus cytology suggest that this strategy is well within the boundaries of currently accepted medical guidelines. Optimistically, 95% of patients would be spared the discomfort and inconvenience of cystoscopy as well as its unintended consequences. Only patients who have positive UroSEEK, persistent symptoms, or hematuria would undergo cystoscopy. The savings in this approach would be considerable, as we estimate the cost of UroSEEK plus cytology to be less than 1/3 of the cost of cystoscopy.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Patients and samples</title><sec id="s4-1-1"><title>BC early detection and BC surveillance cohorts</title><p>Urine samples were collected prospectively from patients in four participating institutions, including Johns Hopkins Hospital, Baltimore, MD, USA; A.C. Camargo Cancer Center, Sao Paulo, Brazil; Osaka University Hospital, Osaka, Japan; and Hacettepe University Hospital, Ankara, Turkey. The study was approved by the Institutional Review Boards of Johns Hopkins Hospital and all other participating institutions. Material transfer agreements were obtained. Patients with a known history of malignancy other than BC were excluded from the study. The BC early detection cohort comprised patients who were referred to a urology clinic in one of the above hospitals because of hematuria or lower urinary tract symptoms (570 patients; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). The other cohort (322 patients) represented patients with prior established diagnosis of BC who are on surveillance for disease recurrence (BC surveillance cohort). As noted in the main text, the primary tumors from these patients harbored mutations in at least one of the 11 genes assessed through the multiplex or singleplex assays. A minimum of 12 months of follow-up from the date of urine collection was required in cases with no evidence of incident (BC early detection cohort) or recurrent tumors (BC Surveillance cohort) to be included in the study. Urine samples were collected before any procedures, such as cystoscopy, were performed during patient visits. A total of 892 urine samples were analyzed and composed of two types of samples. The first was residual urinary cells after processing with standard BD SurePath liquid-based cytology protocols (Becton Dickinson and Company; Franklin Lakes, NJ, USA). To allow for standard-of-care, residual SurePath fluids were kept refrigerated for 6–8 weeks before submission for DNA purification to allow for any potential need for repeat cytology processing of the same sample. The second sample type was composed of bio-banked fresh urine samples in which 15–25 mL of voided urine samples were stored at 4˚C for up to 60 min prior to centrifugation (10 min at 500 <italic>g</italic>) and the pellets stored at minus 80˚C before DNA purification.</p><p>Formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from trans-urethral resections (TURB) or cystectomies were collected in 413 of the 892 cases. When several different tumors from the same patient were available (because of recurrences), the earliest tumor tissue obtained following donation of the urine sample was used in the early detection cohort. In the Surveillance cohort, tumors obtained before the donation of the urine sample were used in 146 of the 322 patients. In the other 176 Surveillance cases, the earliest tissue obtained following the donation of the urine sample was used. A genitourinary pathologist reviewed all histologic slides to confirm the diagnosis and select a representative tumor area with as high tumor cellularity as possible for that case. Corresponding FFPE blocks were cored with a sterile 16-gauge needle. One to three cores were obtained per tumor and placed in 1.5 mL sterile tubes for DNA purification, as previously described (<xref ref-type="bibr" rid="bib43">Kinde et al., 2013</xref>). Electronic medical records were reviewed to obtain medical history and follow up data in all patients.</p></sec><sec id="s4-1-2"><title>UTUC cohort</title><p>Sequential patients with UTUC scheduled to undergo a radical unilateral nephroureterectomy at National Taiwan University Hospital, Taipei Taiwan, in 2012 - 2016 were asked to participate in the study. All patients provided informed consent using the consent form and study design reviewed and approved by the Institutional Review Boards at National Taiwan University and Stony Brook University. A total of 56 UTUC patients were enrolled in the study after excluding four patients with gross hematuria and one patient with a tumor-urine DNA mismatch by identity testing (see below).</p><p>UTUC patients provided urine samples (12 hr collection (<italic>n</italic> = 10); spot urines (<italic>n</italic> = 41); spot and 12 hr collection (<italic>n</italic> = 4); bladder wash (<italic>n</italic> = 1)) one day prior to surgery. Urinary cells were isolated by centrifugation at 581 <italic>g</italic> for 10 min at room temperature, washed three times in saline using the same centrifugation conditions, and stored frozen until DNA was isolated using a Qiagen kit #937255 (Germantown, MD). DNA was purified from fresh-frozen resected samples of upper tract tumors and renal cortex by standard phenol-chloroform extraction procedures (<xref ref-type="bibr" rid="bib9">Chen et al., 2012</xref>; <xref ref-type="bibr" rid="bib37">Jelaković et al., 2012</xref>). One upper urinary tract tumor per patient was analyzed; for cases with tumors at multiple sites, renal pelvic tumors were preferentially selected whenever available. FFPE tumor samples were staged and graded by a urologic pathologist, and the presence of one or more UTUC was confirmed by histopathology for each enrolled individual. Pertinent clinical and demographic data were obtained by a chart review of each individual. eGFR was calculated with the MDRD equation (<xref ref-type="bibr" rid="bib48">Levey et al., 2006</xref>) and used to determine CKD stage (<xref ref-type="bibr" rid="bib47">Levey et al., 2005</xref>).</p></sec></sec><sec id="s4-2"><title>DNA adduct analysis</title><p>AL-DNA adduct (7-(deoxyadenosin-<italic>N</italic><sup>6</sup>-yl) aristolactam I; dA-AL-I) levels in 2 µg of DNA from the normal renal cortex of UTUC patients were quantified with ultra-performance liquid chromatography–electrospray ionization/multistage mass spectrometry (UPLC-ESI/MS<sup>n</sup>) with a linear quadrupole ion trap mass spectrometer (LTQ Velos Pro, Thermo Fisher Scientific, San Jose, CA) as described previously (<xref ref-type="bibr" rid="bib97">Yun et al., 2012</xref>).</p></sec><sec id="s4-3"><title>Mutation analysis</title><p>Three separate assays were used to search for abnormalities in urinary cell DNA. First, a multiplex PCR was used to detect mutations in regions of ten genes commonly mutated in urologic malignancies: <italic>CDKN2A, ERBB2, FGFR3, HRAS, KRAS, MET, MLL, PIK3CA, TP53, and VHL</italic> (<xref ref-type="bibr" rid="bib7">Cancer Genome Atlas Research Network, 2014</xref>; <xref ref-type="bibr" rid="bib50">Lin et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Mo et al., 2007</xref>; <xref ref-type="bibr" rid="bib60">Netto, 2011</xref>; <xref ref-type="bibr" rid="bib72">Sarkis et al., 1995</xref>; <xref ref-type="bibr" rid="bib71">Sarkis et al., 1994</xref>; <xref ref-type="bibr" rid="bib70">Sarkis et al., 1993</xref>; <xref ref-type="bibr" rid="bib93">Wu, 2005</xref>). The 57 primer pairs used for this multiplex PCR were divided in a total of three multiplex reactions, each containing non-overlapping amplicons (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). These primers were used to amplify DNA in 25 µL reactions as previously described (<xref ref-type="bibr" rid="bib41">Kinde et al., 2011</xref>), except that 15 cycles were used for the initial amplification. Second, the <italic>TERT</italic> promoter region was evaluated. A single amplification primer was used to amplify a 73 bp segment containing the region of the <italic>TERT</italic> promoter known to harbor mutations in BC and UTUC (<xref ref-type="bibr" rid="bib40">Killela et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Kinde et al., 2013</xref>). The conditions used to amplify it were the same as those used in the multiplex reactions described above except that Phusion GC Buffer (Thermo-Fisher) rather than HF buffer was used, and 20 cycles were used for the initial amplification. The <italic>TERT</italic> promoter region was not included in the multiplex PCR because of its high GC content.</p><p>PCR products were purified with AMPure XP beads (Beckman Coulter, PA, USA) and 0.25% of the purified PCR products (multiplex) or 0.0125% of the PCR products (<italic>TERT</italic> singleplex) were then amplified in a second round of PCR, as described by <xref ref-type="bibr" rid="bib91">Wang et al., 2016</xref>. PCR products from the second round of amplification were then purified with AMPure and sequenced on an Illumina instrument. For each mutation identified, the mutant allele frequency (MAF) was determined by dividing the number of uniquely identified reads with mutations (<xref ref-type="bibr" rid="bib41">Kinde et al., 2011</xref>) by the total number of uniquely identified reads. Each DNA sample was assessed in two independent PCRs, for both the <italic>TERT</italic> promoter and multiplex assays, and samples were scored as positive only if both PCRs showed the same mutation. The MAFs and number of UIDs listed in the Supplementary Tables refer to the average of the two independent assays. All coordinates are reported relative to genome reference hg19.</p><p>To evaluate the statistical significance of putative mutations, we assessed DNA from white blood cells (WBCs) of 188 unrelated healthy individuals. A variant observed in the samples from the BC or UTUC cohorts was only scored as a mutation if it was observed at a much higher MAF than observed in normal WBCs. Specifically, the classification of a sample’s DNA status was based on two complementary criteria applied to each mutation: 1) the difference between the average MAF in the sample of interest and the corresponding maximum MAF observed for that same mutation in a set of controls; and 2) the Stouffer’s Z-score obtained by comparing the MAF in the sample of interest to a distribution of normal controls. To calculate the Z-score, the MAF in the sample of interest was normalized based on the mutation-specific distributions of MAFs observed among all controls. Following this mutation-specific normalization, a <italic>P</italic>-value was obtained by comparing the MAF of each mutation in each well with a reference distribution of MAFs built from normal controls where all mutations were included. The Stouffer’s Z-score was then calculated from the <italic>P</italic>-values of two wells, weighted by their number of UIDs. The sample was classified as positive if either the difference or the Stouffer’s Z-score of its mutations was above the thresholds determined from the normal WBCs. The threshold for the difference parameter was defined by the highest MAF observed in any normal WBCs. The threshold for the Stouffer's Z-score was chosen to allow one false positive among the 188 normal urine samples studied (see below).</p></sec><sec id="s4-4"><title>Analysis of aneuploidy</title><p>Aneuploidy was assessed with FastSeqS, which uses a single primer pair to amplify ~38,000 loci scattered throughout the genome (<xref ref-type="bibr" rid="bib42">Kinde et al., 2012</xref>). After massively parallel sequencing, gains or losses of each of the 39 chromosome arms covered by the assay were determined using a bespoke statistical learning method described in <xref ref-type="bibr" rid="bib16">Douville et al., 2018</xref>. A support vector machine (SVM) was used to discriminate between aneuploid and euploid samples. The SVM was trained using 3150 low neoplastic cell fraction synthetic aneuploid samples and 677 euploid peripheral WBC samples. Samples were scored as positive when the genome-wide aneuploidy score was &gt;0.7, and there was at least one gain or loss of a chromosome arm.</p></sec><sec id="s4-5"><title>Identity checks</title><p>A multiplex reaction containing 26 primers detecting 31 common SNPs on chromosomes 10 and 20 was performed using the amplification conditions described above for the multiplex PCR. The 26 primers used for this identity evaluation are listed in <xref ref-type="supplementary-material" rid="supp21">Supplementary file 21</xref>.</p></sec><sec id="s4-6"><title>Normal control samples</title><p>Urine samples from 188 healthy volunteers (19–60 years; mean age 26 years) were obtained and processed identically to the bio-banked fresh urine samples as described above. Urinary cell DNA from these 188 samples was used to assess the specificity of the UroSEEK test. WBC DNA from 94 normal individuals was used to evaluate the technical specificity of the PCR analysis.</p></sec><sec id="s4-7"><title>Statistical analysis</title><p>Performance characteristics of urine cytology, UroSEEK and its three components were calculated using MedCalc statistical software, online version (<ext-link ext-link-type="uri" xlink:href="https://www.medcalc.org/calc/diagnostic_test.php">https://www.medcalc.org/calc/diagnostic_test.php</ext-link>). Confidence intervals (95%) were determined with an online GraphPad Software Inc. statistical calculator (<ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/quickcalcs/confInterval1/">https://www.graphpad.com/quickcalcs/confInterval1/</ext-link>) using the modified Wald method.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This research was supported by grants from the National Science Council, Taiwan to CHC (104–2314-B-002–132) and to YSP (104–2314-B-002–121-MY3). We appreciate the clinical services provided by Dr. Kuo-How Huang, Shuo-Meng Wang, Huai-Ching Tai and Yuan-Ju Lee (Department of Urology, National Taiwan University Hospital). We are grateful for the generous support provided by Henry and Marsha Laufer, the Virginia and DK Ludwig Fund for Cancer Research, the Commonwealth Foundation, the John Templeton Foundation, and the Conrad R Hilton Foundation. All sequencing was performed at the Sol Goldman Sequencing Facility at Johns Hopkins. This work was also supported by grants from the NIH (Grants CA-77598, CA 06973, GM 07309, and ES019564). The authors appreciate the medical illustrations skillfully designed by Kathleen Gebhart (Media Services, Stony Brook University). The authors appreciate the help in editing by Janice Nigro.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics. LAD holds equity in PapGene, Personal Genome Diagnostics (PGDx) and Phoremost. He is a paid consultant for Merck, PGDx and Phoremost. LAD is an inventor of licensed intellectual property related to technology for ctDNA analyses and mismatch repair deficiency for diagnosis and therapy from Johns Hopkins University. These licenses and relationships are associated with equity or royalty payments to LAD. The terms of all these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. In addition, in the past 5 years, LAD has participated as a paid consultant for one-time engagements with Caris, Lyndra, Genocea Biosciences, Illumina and Cell Design Labs.</p></fn><fn fn-type="COI-statement" id="conf3"><p>Founder of Personal Genome Diagnostics and PapGene and advises Sysmex-Inostics. These companies and others have licensed technologies from Johns Hopkins, of which BV, KK, and NP are inventors on a patent (U.S. 20140227705 A1) and receive royalties. The terms of these arrangements are managed by the university in accordance with its conflict of interest policies.</p></fn><fn fn-type="COI-statement" id="conf4"><p>Ken W Kinzler: Founder of Personal Genome Diagnostics and PapGene and advises Sysmex-Inostics. These companies and others have licensed technologies from Johns Hopkins, of which BV, KK, and NP are inventors on a patent (U.S. 20140227705 A1) and receive royalties. The terms of these arrangements are managed by the university in accordance with its conflict of interest policies.</p></fn><fn fn-type="COI-statement" id="conf5"><p>Bert Vogelstein: Founder of Personal Genome Diagnostics and PapGene and advises Sysmex-Inostics. These companies and others have licensed technologies from Johns Hopkins, of which BV, KK, and NP are inventors on a patent (U.S. 20140227705 A1) and receive royalties. The terms of these arrangements are managed by the university in accordance with its conflict of interest policies.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Resources, Formal analysis, Validation, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Writing—review and editing, Project administration, Resources, Funding acquisition</p></fn><fn fn-type="con" id="con3"><p>Resources, Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con8"><p>Resources, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con13"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Writing—review and editing</p></fn><fn fn-type="con" id="con15"><p>Formal analysis</p></fn><fn fn-type="con" id="con16"><p>Resources, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con17"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con18"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con19"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con20"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con21"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con22"><p>Formal analysis</p></fn><fn fn-type="con" id="con23"><p>Investigation</p></fn><fn fn-type="con" id="con24"><p>Conceptualization, Funding acquisition, Writing—review and editing</p></fn><fn fn-type="con" id="con25"><p>Conceptualization, Writing—review and editing</p></fn><fn fn-type="con" id="con26"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con27"><p>Investigation</p></fn><fn fn-type="con" id="con28"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con29"><p>Investigation</p></fn><fn fn-type="con" id="con30"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con31"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con32"><p>Writing—review and editing</p></fn><fn fn-type="con" id="con33"><p>Resources, Supervision, Funding acquisition, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con34"><p>Conceptualization, Visualization</p></fn><fn fn-type="con" id="con35"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con36"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con37"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con38"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con39"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con40"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: The study was approved by the Institutional Review Boards of Johns Hopkins Hospital and all other participating institutions. Proper material transfer agreements were obtained. Patients with a known history of malignancy other than urothelial cancer were excluded from the study. Additionally all UTUC patients provided informed consent using the consent form and study design reviewed and approved by the Institutional Review Boards at National Taiwan University and Stony Brook University. Consent to publish results was also obtained from all parties involved.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.32143.010</object-id><label>Supplementary file 1.</label><caption><title>Development of PCR-based assays to identify tumor-specific mutations in urinary cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><object-id pub-id-type="doi">10.7554/eLife.32143.011</object-id><label>Supplementary file 2.</label><caption><title>Demographic and clinical features of the BC early detection cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><object-id pub-id-type="doi">10.7554/eLife.32143.012</object-id><label>Supplementary file 3.</label><caption><title>Mutations detected by Multiplex Assay in primary tumor tissues from the early detection cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="supp4"><object-id pub-id-type="doi">10.7554/eLife.32143.013</object-id><label>Supplementary file 4.</label><caption><title>Primers used to detect mutations in the 10-gene multiplex panel and TERT.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp4-v2.xlsx"/></supplementary-material><supplementary-material id="supp5"><object-id pub-id-type="doi">10.7554/eLife.32143.014</object-id><label>Supplementary file 5.</label><caption><title>Mutations detected by the 10-gene Multiplex Assay in urine samples from the early detection cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp5-v2.xlsx"/></supplementary-material><supplementary-material id="supp6"><object-id pub-id-type="doi">10.7554/eLife.32143.015</object-id><label>Supplementray file 6.</label><caption><title>Mutations detected by the TERT Assay in urine samples from the early detection cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-fig6-v2.xlsx"/></supplementary-material><supplementary-material id="supp7"><object-id pub-id-type="doi">10.7554/eLife.32143.016</object-id><label>Supplementary file 7.</label><caption><title>Chromosome arm gains and losses detected by the Aneuploidy Assay in urine samples from early detection cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp7-v2.xlsx"/></supplementary-material><supplementary-material id="supp8"><object-id pub-id-type="doi">10.7554/eLife.32143.017</object-id><label>Supplementary file 8.</label><caption><title>Mutations detected by TERT Assay in primary tumor tissues from the early detection cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp8-v2.xlsx"/></supplementary-material><supplementary-material id="supp9"><object-id pub-id-type="doi">10.7554/eLife.32143.018</object-id><label>Supplementary file 9.</label><caption><title>Individual clinical data for the UTUC cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp9-v2.xlsx"/></supplementary-material><supplementary-material id="supp10"><object-id pub-id-type="doi">10.7554/eLife.32143.019</object-id><label>Supplementary file 10.</label><caption><title>Mutations detected in urinary cell DNA from UTUC patients by the 10-gene multiplex assay.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp10-v2.xlsx"/></supplementary-material><supplementary-material id="supp11"><object-id pub-id-type="doi">10.7554/eLife.32143.020</object-id><label>Supplementary file 11.</label><caption><title>TERT promoter mutations identified in urinary cell DNA from UTUC patients.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp11-v2.xlsx"/></supplementary-material><supplementary-material id="supp12"><object-id pub-id-type="doi">10.7554/eLife.32143.021</object-id><label>Supplementary file 12.</label><caption><title>Urinary cell DNA samples from UTUC patients that scored positive for aneuploidy.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp12-v2.xlsx"/></supplementary-material><supplementary-material id="supp13"><object-id pub-id-type="doi">10.7554/eLife.32143.022</object-id><label>Supplementary file 13.</label><caption><title>Comparison of copy number variations in matched tumor and urinary cell DNA samples from the UTUC cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp13-v2.xlsx"/></supplementary-material><supplementary-material id="supp14"><object-id pub-id-type="doi">10.7554/eLife.32143.023</object-id><label>Supplementary file 14.</label><caption><title>Mutations detected in primary tumor DNA from UTUC patients by the 10-gene multiplex assay.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp14-v2.xlsx"/></supplementary-material><supplementary-material id="supp15"><object-id pub-id-type="doi">10.7554/eLife.32143.024</object-id><label>Supplementary file 15.</label><caption><title>TERT promoter mutations identified in primary tumor DNA from UTUC patients.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp15-v2.xlsx"/></supplementary-material><supplementary-material id="supp16"><object-id pub-id-type="doi">10.7554/eLife.32143.025</object-id><label>Supplementary file 16.</label><caption><title>Demographic and clinical features of the Surveillance Cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp16-v2.xlsx"/></supplementary-material><supplementary-material id="supp17"><object-id pub-id-type="doi">10.7554/eLife.32143.026</object-id><label>Supplementary file 17.</label><caption><title>Mutations detected by the 10-gene Multiplex Assay on urine samples from the BC Surveillance cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp17-v2.xlsx"/></supplementary-material><supplementary-material id="supp18"><object-id pub-id-type="doi">10.7554/eLife.32143.027</object-id><label>Supplementary file 18.</label><caption><title>Mutations detected by the TERT Assay on urine samples from the BC Surveillance cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp18-v2.xlsx"/></supplementary-material><supplementary-material id="supp19"><object-id pub-id-type="doi">10.7554/eLife.32143.028</object-id><label>Supplementary file 19.</label><caption><title>Chromosome arm gains and losses detected by the Aneuploidy Assay in urine samples from the BC Surveillance cohort.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp19-v2.xlsx"/></supplementary-material><supplementary-material id="supp20"><object-id pub-id-type="doi">10.7554/eLife.32143.029</object-id><label>Supplementary file 20.</label><caption><title>Summary of the performance of Cytology vs.UroSEEK in both BC cohort tumors.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp20-v2.xlsx"/></supplementary-material><supplementary-material id="supp21"><object-id pub-id-type="doi">10.7554/eLife.32143.030</object-id><label>Supplementary file 21.</label><caption><title>Primers used for identity matching of tumor and urinary cell DNA samples from UTUC patients.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-32143-supp21-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.32143.031</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-32143-transrepform-v2.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allory</surname> <given-names>Y</given-names></name><name><surname>Beukers</surname> <given-names>W</given-names></name><name><surname>Sagrera</surname> <given-names>A</given-names></name><name><surname>Flández</surname> <given-names>M</given-names></name><name><surname>Marqués</surname> <given-names>M</given-names></name><name><surname>Márquez</surname> <given-names>M</given-names></name><name><surname>van der Keur</surname> <given-names>KA</given-names></name><name><surname>Dyrskjot</surname> <given-names>L</given-names></name><name><surname>Lurkin</surname> <given-names>I</given-names></name><name><surname>Vermeij</surname> <given-names>M</given-names></name><name><surname>Carrato</surname> <given-names>A</given-names></name><name><surname>Lloreta</surname> <given-names>J</given-names></name><name><surname>Lorente</surname> <given-names>JA</given-names></name><name><surname>Carrillo-de Santa Pau</surname> <given-names>E</given-names></name><name><surname>Masius</surname> <given-names>RG</given-names></name><name><surname>Kogevinas</surname> <given-names>M</given-names></name><name><surname>Steyerberg</surname> <given-names>EW</given-names></name><name><surname>van Tilborg</surname> <given-names>AA</given-names></name><name><surname>Abas</surname> <given-names>C</given-names></name><name><surname>Orntoft</surname> <given-names>TF</given-names></name><name><surname>Zuiverloon</surname> <given-names>TC</given-names></name><name><surname>Malats</surname> <given-names>N</given-names></name><name><surname>Zwarthoff</surname> <given-names>EC</given-names></name><name><surname>Real</surname> <given-names>FX</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome</article-title><source>European Urology</source><volume>65</volume><fpage>360</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2013.08.052</pub-id><pub-id pub-id-type="pmid">24018021</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baard</surname> <given-names>J</given-names></name><name><surname>de Bruin</surname> <given-names>DM</given-names></name><name><surname>Zondervan</surname> <given-names>PJ</given-names></name><name><surname>Kamphuis</surname> <given-names>G</given-names></name><name><surname>de la Rosette</surname> <given-names>J</given-names></name><name><surname>Laguna</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Diagnostic dilemmas in patients with upper tract urothelial carcinoma</article-title><source>Nature Reviews Urology</source><volume>14</volume><fpage>181</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2016.252</pub-id><pub-id pub-id-type="pmid">27958391</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansal</surname> <given-names>N</given-names></name><name><surname>Gupta</surname> <given-names>A</given-names></name><name><surname>Sankhwar</surname> <given-names>SN</given-names></name><name><surname>Mahdi</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Low- and high-grade bladder cancer appraisal via serum-based proteomics approach</article-title><source>Clinica Chimica Acta</source><volume>436</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2014.05.012</pub-id><pub-id pub-id-type="pmid">24875752</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barkan</surname> <given-names>GA</given-names></name><name><surname>Wojcik</surname> <given-names>EM</given-names></name><name><surname>Nayar</surname> <given-names>R</given-names></name><name><surname>Savic-Prince</surname> <given-names>S</given-names></name><name><surname>Quek</surname> <given-names>ML</given-names></name><name><surname>Kurtycz</surname> <given-names>DF</given-names></name><name><surname>Rosenthal</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The paris system for reporting urinary cytology: The quest to develop a standardized terminology</article-title><source>Advances in Anatomic Pathology</source><volume>23</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1097/PAP.0000000000000118</pub-id><pub-id pub-id-type="pmid">27233050</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettegowda</surname> <given-names>C</given-names></name><name><surname>Sausen</surname> <given-names>M</given-names></name><name><surname>Leary</surname> <given-names>RJ</given-names></name><name><surname>Kinde</surname> <given-names>I</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Agrawal</surname> <given-names>N</given-names></name><name><surname>Bartlett</surname> <given-names>BR</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Luber</surname> <given-names>B</given-names></name><name><surname>Alani</surname> <given-names>RM</given-names></name><name><surname>Antonarakis</surname> <given-names>ES</given-names></name><name><surname>Azad</surname> <given-names>NS</given-names></name><name><surname>Bardelli</surname> <given-names>A</given-names></name><name><surname>Brem</surname> <given-names>H</given-names></name><name><surname>Cameron</surname> <given-names>JL</given-names></name><name><surname>Lee</surname> <given-names>CC</given-names></name><name><surname>Fecher</surname> <given-names>LA</given-names></name><name><surname>Gallia</surname> <given-names>GL</given-names></name><name><surname>Gibbs</surname> <given-names>P</given-names></name><name><surname>Le</surname> <given-names>D</given-names></name><name><surname>Giuntoli</surname> <given-names>RL</given-names></name><name><surname>Goggins</surname> <given-names>M</given-names></name><name><surname>Hogarty</surname> <given-names>MD</given-names></name><name><surname>Holdhoff</surname> <given-names>M</given-names></name><name><surname>Hong</surname> <given-names>SM</given-names></name><name><surname>Jiao</surname> <given-names>Y</given-names></name><name><surname>Juhl</surname> <given-names>HH</given-names></name><name><surname>Kim</surname> <given-names>JJ</given-names></name><name><surname>Siravegna</surname> <given-names>G</given-names></name><name><surname>Laheru</surname> <given-names>DA</given-names></name><name><surname>Lauricella</surname> <given-names>C</given-names></name><name><surname>Lim</surname> <given-names>M</given-names></name><name><surname>Lipson</surname> <given-names>EJ</given-names></name><name><surname>Marie</surname> <given-names>SK</given-names></name><name><surname>Netto</surname> <given-names>GJ</given-names></name><name><surname>Oliner</surname> <given-names>KS</given-names></name><name><surname>Olivi</surname> <given-names>A</given-names></name><name><surname>Olsson</surname> <given-names>L</given-names></name><name><surname>Riggins</surname> <given-names>GJ</given-names></name><name><surname>Sartore-Bianchi</surname> <given-names>A</given-names></name><name><surname>Schmidt</surname> <given-names>K</given-names></name><name><surname>Shih</surname> <given-names>lM</given-names></name><name><surname>Oba-Shinjo</surname> <given-names>SM</given-names></name><name><surname>Siena</surname> <given-names>S</given-names></name><name><surname>Theodorescu</surname> <given-names>D</given-names></name><name><surname>Tie</surname> <given-names>J</given-names></name><name><surname>Harkins</surname> <given-names>TT</given-names></name><name><surname>Veronese</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>TL</given-names></name><name><surname>Weingart</surname> <given-names>JD</given-names></name><name><surname>Wolfgang</surname> <given-names>CL</given-names></name><name><surname>Wood</surname> <given-names>LD</given-names></name><name><surname>Xing</surname> <given-names>D</given-names></name><name><surname>Hruban</surname> <given-names>RH</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Allen</surname> <given-names>PJ</given-names></name><name><surname>Schmidt</surname> <given-names>CM</given-names></name><name><surname>Choti</surname> <given-names>MA</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Detection of circulating tumor DNA in early- and late-stage human malignancies</article-title><source>Science Translational Medicine</source><volume>6</volume><elocation-id>224ra24</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3007094</pub-id><pub-id pub-id-type="pmid">24553385</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botezatu</surname> <given-names>I</given-names></name><name><surname>Serdyuk</surname> <given-names>O</given-names></name><name><surname>Potapova</surname> <given-names>G</given-names></name><name><surname>Shelepov</surname> <given-names>V</given-names></name><name><surname>Alechina</surname> <given-names>R</given-names></name><name><surname>Molyaka</surname> <given-names>Y</given-names></name><name><surname>Ananév</surname> <given-names>V</given-names></name><name><surname>Bazin</surname> <given-names>I</given-names></name><name><surname>Garin</surname> <given-names>A</given-names></name><name><surname>Narimanov</surname> <given-names>M</given-names></name><name><surname>Knysh</surname> <given-names>V</given-names></name><name><surname>Melkonyan</surname> <given-names>H</given-names></name><name><surname>Umansky</surname> <given-names>S</given-names></name><name><surname>Lichtenstein</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism</article-title><source>Clinical chemistry</source><volume>46</volume><fpage>1078</fpage><lpage>1084</lpage><pub-id pub-id-type="pmid">10926886</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Comprehensive molecular characterization of urothelial bladder carcinoma</article-title><source>Nature</source><volume>507</volume><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1038/nature12965</pub-id><pub-id pub-id-type="pmid">24476821</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname> <given-names>H</given-names></name><name><surname>Brown</surname> <given-names>RE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Field effect in cancer-an update</article-title><source>Annals of Clinical and Laboratory Science</source><volume>39</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">19880759</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>CH</given-names></name><name><surname>Dickman</surname> <given-names>KG</given-names></name><name><surname>Moriya</surname> <given-names>M</given-names></name><name><surname>Zavadil</surname> <given-names>J</given-names></name><name><surname>Sidorenko</surname> <given-names>VS</given-names></name><name><surname>Edwards</surname> <given-names>KL</given-names></name><name><surname>Gnatenko</surname> <given-names>DV</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Turesky</surname> <given-names>RJ</given-names></name><name><surname>Wu</surname> <given-names>XR</given-names></name><name><surname>Pu</surname> <given-names>YS</given-names></name><name><surname>Grollman</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Aristolochic acid-associated urothelial cancer in Taiwan</article-title><source>PNAS</source><volume>109</volume><fpage>8241</fpage><lpage>8246</lpage><pub-id pub-id-type="doi">10.1073/pnas.1119920109</pub-id><pub-id pub-id-type="pmid">22493262</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>CH</given-names></name><name><surname>Dickman</surname> <given-names>KG</given-names></name><name><surname>Huang</surname> <given-names>CY</given-names></name><name><surname>Moriya</surname> <given-names>M</given-names></name><name><surname>Shun</surname> <given-names>CT</given-names></name><name><surname>Tai</surname> <given-names>HC</given-names></name><name><surname>Huang</surname> <given-names>KH</given-names></name><name><surname>Wang</surname> <given-names>SM</given-names></name><name><surname>Lee</surname> <given-names>YJ</given-names></name><name><surname>Grollman</surname> <given-names>AP</given-names></name><name><surname>Pu</surname> <given-names>YS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes</article-title><source>International Journal of Cancer</source><volume>133</volume><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1002/ijc.28013</pub-id><pub-id pub-id-type="pmid">23292929</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>L</given-names></name><name><surname>Montironi</surname> <given-names>R</given-names></name><name><surname>Lopez-Beltran</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TERT Promoter mutations occur frequently in urothelial papilloma and papillary urothelial neoplasm of low malignant potential</article-title><source>European Urology</source><volume>71</volume><fpage>497</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2016.12.008</pub-id><pub-id pub-id-type="pmid">28040359</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan</surname> <given-names>ML</given-names></name><name><surname>Springer</surname> <given-names>S</given-names></name><name><surname>Nguyen</surname> <given-names>D</given-names></name><name><surname>Taheri</surname> <given-names>D</given-names></name><name><surname>Guner</surname> <given-names>G</given-names></name><name><surname>Mendoza Rodriguez</surname> <given-names>MA</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Kinde</surname> <given-names>I</given-names></name><name><surname>Del Carmen Rodriguez Pena</surname> <given-names>M</given-names></name><name><surname>VandenBussche</surname> <given-names>CJ</given-names></name><name><surname>Olson</surname> <given-names>MT</given-names></name><name><surname>Cunha</surname> <given-names>I</given-names></name><name><surname>Fujita</surname> <given-names>K</given-names></name><name><surname>Ertoy</surname> <given-names>D</given-names></name><name><surname>Kinzler</surname> <given-names>K</given-names></name><name><surname>Bivalacqua</surname> <given-names>T</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Netto</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder</article-title><source>Human Pathology</source><volume>53</volume><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2016.02.009</pub-id><pub-id pub-id-type="pmid">26980028</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname> <given-names>R</given-names></name><name><surname>Jones</surname> <given-names>JS</given-names></name><name><surname>Barocas</surname> <given-names>DA</given-names></name><name><surname>Castle</surname> <given-names>EP</given-names></name><name><surname>Lang</surname> <given-names>EK</given-names></name><name><surname>Leveillee</surname> <given-names>RJ</given-names></name><name><surname>Messing</surname> <given-names>EM</given-names></name><name><surname>Miller</surname> <given-names>SD</given-names></name><name><surname>Peterson</surname> <given-names>AC</given-names></name><name><surname>Turk</surname> <given-names>TM</given-names></name><name><surname>Weitzel</surname> <given-names>W</given-names></name><name><surname>American Urological</surname> <given-names>A</given-names></name><collab>American Urological Association</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline</article-title><source>The Journal of Urology</source><volume>188</volume><fpage>2473</fpage><lpage>2481</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2012.09.078</pub-id><pub-id pub-id-type="pmid">23098784</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname> <given-names>SJ</given-names></name><name><surname>Tsui</surname> <given-names>DW</given-names></name><name><surname>Murtaza</surname> <given-names>M</given-names></name><name><surname>Biggs</surname> <given-names>H</given-names></name><name><surname>Rueda</surname> <given-names>OM</given-names></name><name><surname>Chin</surname> <given-names>SF</given-names></name><name><surname>Dunning</surname> <given-names>MJ</given-names></name><name><surname>Gale</surname> <given-names>D</given-names></name><name><surname>Forshew</surname> <given-names>T</given-names></name><name><surname>Mahler-Araujo</surname> <given-names>B</given-names></name><name><surname>Rajan</surname> <given-names>S</given-names></name><name><surname>Humphray</surname> <given-names>S</given-names></name><name><surname>Becq</surname> <given-names>J</given-names></name><name><surname>Halsall</surname> <given-names>D</given-names></name><name><surname>Wallis</surname> <given-names>M</given-names></name><name><surname>Bentley</surname> <given-names>D</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Rosenfeld</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Analysis of circulating tumor DNA to monitor metastatic breast cancer</article-title><source>New England Journal of Medicine</source><volume>368</volume><fpage>1199</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1213261</pub-id><pub-id pub-id-type="pmid">23484797</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimashkieh</surname> <given-names>H</given-names></name><name><surname>Wolff</surname> <given-names>DJ</given-names></name><name><surname>Smith</surname> <given-names>TM</given-names></name><name><surname>Houser</surname> <given-names>PM</given-names></name><name><surname>Nietert</surname> <given-names>PJ</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation</article-title><source>Cancer Cytopathology</source><volume>121</volume><fpage>591</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1002/cncy.21327</pub-id><pub-id pub-id-type="pmid">23801650</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douville</surname> <given-names>C</given-names></name><name><surname>Springer</surname> <given-names>S</given-names></name><name><surname>Kinde</surname> <given-names>I</given-names></name><name><surname>Cohen</surname> <given-names>JD</given-names></name><name><surname>Hruban</surname> <given-names>RH</given-names></name><name><surname>Lennon</surname> <given-names>AM</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Karchin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs)</article-title><source>PNAS</source><volume>115</volume><fpage>1871</fpage><lpage>1876</lpage><pub-id pub-id-type="doi">10.1073/pnas.1717846115</pub-id><pub-id pub-id-type="pmid">29432176</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dressman</surname> <given-names>D</given-names></name><name><surname>Yan</surname> <given-names>H</given-names></name><name><surname>Traverso</surname> <given-names>G</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations</article-title><source>PNAS</source><volume>100</volume><fpage>8817</fpage><lpage>8822</lpage><pub-id pub-id-type="doi">10.1073/pnas.1133470100</pub-id><pub-id pub-id-type="pmid">12857956</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellinger</surname> <given-names>J</given-names></name><name><surname>Müller</surname> <given-names>SC</given-names></name><name><surname>Dietrich</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epigenetic biomarkers in the blood of patients with urological malignancies</article-title><source>Expert Review of Molecular Diagnostics</source><volume>15</volume><fpage>505</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1586/14737159.2015.1019477</pub-id><pub-id pub-id-type="pmid">25719388</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forshew</surname> <given-names>T</given-names></name><name><surname>Murtaza</surname> <given-names>M</given-names></name><name><surname>Parkinson</surname> <given-names>C</given-names></name><name><surname>Gale</surname> <given-names>D</given-names></name><name><surname>Tsui</surname> <given-names>DW</given-names></name><name><surname>Kaper</surname> <given-names>F</given-names></name><name><surname>Dawson</surname> <given-names>SJ</given-names></name><name><surname>Piskorz</surname> <given-names>AM</given-names></name><name><surname>Jimenez-Linan</surname> <given-names>M</given-names></name><name><surname>Bentley</surname> <given-names>D</given-names></name><name><surname>Hadfield</surname> <given-names>J</given-names></name><name><surname>May</surname> <given-names>AP</given-names></name><name><surname>Caldas</surname> <given-names>C</given-names></name><name><surname>Brenton</surname> <given-names>JD</given-names></name><name><surname>Rosenfeld</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA</article-title><source>Science Translational Medicine</source><volume>4</volume><elocation-id>ra168</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3003726</pub-id><pub-id pub-id-type="pmid">22649089</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fradet</surname> <given-names>Y</given-names></name><name><surname>Lockhard</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark</article-title><source>The Canadian Journal of Urology</source><volume>4</volume><fpage>400</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">12735818</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golan</surname> <given-names>S</given-names></name><name><surname>Nadu</surname> <given-names>A</given-names></name><name><surname>Lifshitz</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The role of diagnostic ureteroscopy in the era of computed tomography urography</article-title><source>BMC Urology</source><volume>15</volume><elocation-id>74</elocation-id><pub-id pub-id-type="doi">10.1186/s12894-015-0068-8</pub-id><pub-id pub-id-type="pmid">26209444</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodison</surname> <given-names>S</given-names></name><name><surname>Chang</surname> <given-names>M</given-names></name><name><surname>Dai</surname> <given-names>Y</given-names></name><name><surname>Urquidi</surname> <given-names>V</given-names></name><name><surname>Rosser</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A multi-analyte assay for the non-invasive detection of bladder cancer</article-title><source>PLoS One</source><volume>7</volume><elocation-id>e47469</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0047469</pub-id><pub-id pub-id-type="pmid">23094052</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gopalakrishna</surname> <given-names>A</given-names></name><name><surname>Fantony</surname> <given-names>JJ</given-names></name><name><surname>Longo</surname> <given-names>TA</given-names></name><name><surname>Owusu</surname> <given-names>R</given-names></name><name><surname>Foo</surname> <given-names>WC</given-names></name><name><surname>Dash</surname> <given-names>R</given-names></name><name><surname>Denton</surname> <given-names>BT</given-names></name><name><surname>Inman</surname> <given-names>BA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Anticipatory Positive Urine Tests for Bladder Cancer</article-title><source>Annals of Surgical Oncology</source><volume>24</volume><fpage>1747</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1245/s10434-016-5763-5</pub-id><pub-id pub-id-type="pmid">28074325</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname> <given-names>DA</given-names></name><name><surname>Rink</surname> <given-names>M</given-names></name><name><surname>Xylinas</surname> <given-names>E</given-names></name><name><surname>Matin</surname> <given-names>SF</given-names></name><name><surname>Stenzl</surname> <given-names>A</given-names></name><name><surname>Roupret</surname> <given-names>M</given-names></name><name><surname>Karakiewicz</surname> <given-names>PI</given-names></name><name><surname>Scherr</surname> <given-names>DS</given-names></name><name><surname>Shariat</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Urothelial carcinoma of the bladder and the upper tract: disparate twins</article-title><source>The Journal of Urology</source><volume>189</volume><fpage>1214</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2012.05.079</pub-id><pub-id pub-id-type="pmid">23023150</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Grollman</surname> <given-names>AP</given-names></name><name><surname>Scarborough</surname> <given-names>J</given-names></name><name><surname>Jelakovic</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><person-group person-group-type="editor"><name><surname>Fishbein</surname> <given-names>J</given-names></name></person-group><source>Aristolochic Acid Nephropathy: An Environmental and Iatrogenic Disease</source><publisher-name>Elsevier</publisher-name></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grollman</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease</article-title><source>Environmental and Molecular Mutagenesis</source><volume>54</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/em.21756</pub-id><pub-id pub-id-type="pmid">23238808</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haber</surname> <given-names>DA</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA</article-title><source>Cancer Discovery</source><volume>4</volume><fpage>650</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-1014</pub-id><pub-id pub-id-type="pmid">24801577</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajdinjak</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing</article-title><source>Urologic Oncology: Seminars and Original Investigations</source><volume>26</volume><fpage>646</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1016/j.urolonc.2007.06.002</pub-id><pub-id pub-id-type="pmid">18367109</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoang</surname> <given-names>ML</given-names></name><name><surname>Chen</surname> <given-names>CH</given-names></name><name><surname>Sidorenko</surname> <given-names>VS</given-names></name><name><surname>He</surname> <given-names>J</given-names></name><name><surname>Dickman</surname> <given-names>KG</given-names></name><name><surname>Yun</surname> <given-names>BH</given-names></name><name><surname>Moriya</surname> <given-names>M</given-names></name><name><surname>Niknafs</surname> <given-names>N</given-names></name><name><surname>Douville</surname> <given-names>C</given-names></name><name><surname>Karchin</surname> <given-names>R</given-names></name><name><surname>Turesky</surname> <given-names>RJ</given-names></name><name><surname>Pu</surname> <given-names>YS</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Grollman</surname> <given-names>AP</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Rosenquist</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing</article-title><source>Science Translational Medicine</source><volume>5</volume><elocation-id>ra102</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3006200</pub-id><pub-id pub-id-type="pmid">23926200</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollstein</surname> <given-names>M</given-names></name><name><surname>Moriya</surname> <given-names>M</given-names></name><name><surname>Grollman</surname> <given-names>AP</given-names></name><name><surname>Olivier</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid</article-title><source>Mutation Research/Reviews in Mutation Research</source><volume>753</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.mrrev.2013.02.003</pub-id><pub-id pub-id-type="pmid">23422071</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname> <given-names>S</given-names></name><name><surname>Figl</surname> <given-names>A</given-names></name><name><surname>Rachakonda</surname> <given-names>PS</given-names></name><name><surname>Fischer</surname> <given-names>C</given-names></name><name><surname>Sucker</surname> <given-names>A</given-names></name><name><surname>Gast</surname> <given-names>A</given-names></name><name><surname>Kadel</surname> <given-names>S</given-names></name><name><surname>Moll</surname> <given-names>I</given-names></name><name><surname>Nagore</surname> <given-names>E</given-names></name><name><surname>Hemminki</surname> <given-names>K</given-names></name><name><surname>Schadendorf</surname> <given-names>D</given-names></name><name><surname>Kumar</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TERT promoter mutations in familial and sporadic melanoma</article-title><source>Science</source><volume>339</volume><fpage>959</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1126/science.1230062</pub-id><pub-id pub-id-type="pmid">23348503</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname> <given-names>SC</given-names></name><name><surname>Lin</surname> <given-names>IH</given-names></name><name><surname>Tseng</surname> <given-names>WL</given-names></name><name><surname>Lee</surname> <given-names>CH</given-names></name><name><surname>Wang</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003</article-title><source>Chinese Medicine</source><volume>3</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/1749-8546-3-13</pub-id><pub-id pub-id-type="pmid">18945373</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>SL</given-names></name><name><surname>Zhang</surname> <given-names>HQ</given-names></name><name><surname>Chan</surname> <given-names>K</given-names></name><name><surname>Mei</surname> <given-names>QX</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Studies on the toxicity of Aristolochia manshuriensis (Guanmuton)</article-title><source>Toxicology</source><volume>198</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2004.01.026</pub-id><pub-id pub-id-type="pmid">15138042</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>FW</given-names></name><name><surname>Hodis</surname> <given-names>E</given-names></name><name><surname>Xu</surname> <given-names>MJ</given-names></name><name><surname>Kryukov</surname> <given-names>GV</given-names></name><name><surname>Chin</surname> <given-names>L</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Highly recurrent TERT promoter mutations in human melanoma</article-title><source>Science</source><volume>339</volume><fpage>957</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1126/science.1229259</pub-id><pub-id pub-id-type="pmid">23348506</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname> <given-names>PA</given-names></name><name><surname>Moch</surname> <given-names>H</given-names></name><name><surname>Cubilla</surname> <given-names>AL</given-names></name><name><surname>Ulbright</surname> <given-names>TM</given-names></name><name><surname>Reuter</surname> <given-names>VE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours</article-title><source>European Urology</source><volume>70</volume><fpage>106</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2016.02.028</pub-id><pub-id pub-id-type="pmid">26996659</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname> <given-names>CD</given-names></name><name><surname>Platt</surname> <given-names>FM</given-names></name><name><surname>Knowles</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine</article-title><source>European Urology</source><volume>65</volume><fpage>367</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2013.08.057</pub-id><pub-id pub-id-type="pmid">24035680</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jelaković</surname> <given-names>B</given-names></name><name><surname>Karanović</surname> <given-names>S</given-names></name><name><surname>Vuković-Lela</surname> <given-names>I</given-names></name><name><surname>Miller</surname> <given-names>F</given-names></name><name><surname>Edwards</surname> <given-names>KL</given-names></name><name><surname>Nikolić</surname> <given-names>J</given-names></name><name><surname>Tomić</surname> <given-names>K</given-names></name><name><surname>Slade</surname> <given-names>N</given-names></name><name><surname>Brdar</surname> <given-names>B</given-names></name><name><surname>Turesky</surname> <given-names>RJ</given-names></name><name><surname>Stipančić</surname> <given-names>Ž</given-names></name><name><surname>Dittrich</surname> <given-names>D</given-names></name><name><surname>Grollman</surname> <given-names>AP</given-names></name><name><surname>Dickman</surname> <given-names>KG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid</article-title><source>Kidney International</source><volume>81</volume><fpage>559</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.371</pub-id><pub-id pub-id-type="pmid">22071594</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawauchi</surname> <given-names>S</given-names></name><name><surname>Sakai</surname> <given-names>H</given-names></name><name><surname>Ikemoto</surname> <given-names>K</given-names></name><name><surname>Eguchi</surname> <given-names>S</given-names></name><name><surname>Nakao</surname> <given-names>M</given-names></name><name><surname>Takihara</surname> <given-names>H</given-names></name><name><surname>Shimabukuro</surname> <given-names>T</given-names></name><name><surname>Furuya</surname> <given-names>T</given-names></name><name><surname>Oga</surname> <given-names>A</given-names></name><name><surname>Matsuyama</surname> <given-names>H</given-names></name><name><surname>Takahashi</surname> <given-names>M</given-names></name><name><surname>Sasaki</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology</article-title><source>Human Pathology</source><volume>40</volume><fpage>1783</fpage><lpage>1789</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2009.06.011</pub-id><pub-id pub-id-type="pmid">19733894</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khadra</surname> <given-names>MH</given-names></name><name><surname>Pickard</surname> <given-names>RS</given-names></name><name><surname>Charlton</surname> <given-names>M</given-names></name><name><surname>Powell</surname> <given-names>PH</given-names></name><name><surname>Neal</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice</article-title><source>The Journal of Urology</source><volume>163</volume><fpage>524</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(05)67916-5</pub-id><pub-id pub-id-type="pmid">10647670</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killela</surname> <given-names>PJ</given-names></name><name><surname>Reitman</surname> <given-names>ZJ</given-names></name><name><surname>Jiao</surname> <given-names>Y</given-names></name><name><surname>Bettegowda</surname> <given-names>C</given-names></name><name><surname>Agrawal</surname> <given-names>N</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name><name><surname>Friedman</surname> <given-names>AH</given-names></name><name><surname>Friedman</surname> <given-names>H</given-names></name><name><surname>Gallia</surname> <given-names>GL</given-names></name><name><surname>Giovanella</surname> <given-names>BC</given-names></name><name><surname>Grollman</surname> <given-names>AP</given-names></name><name><surname>He</surname> <given-names>TC</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Hruban</surname> <given-names>RH</given-names></name><name><surname>Jallo</surname> <given-names>GI</given-names></name><name><surname>Mandahl</surname> <given-names>N</given-names></name><name><surname>Meeker</surname> <given-names>AK</given-names></name><name><surname>Mertens</surname> <given-names>F</given-names></name><name><surname>Netto</surname> <given-names>GJ</given-names></name><name><surname>Rasheed</surname> <given-names>BA</given-names></name><name><surname>Riggins</surname> <given-names>GJ</given-names></name><name><surname>Rosenquist</surname> <given-names>TA</given-names></name><name><surname>Schiffman</surname> <given-names>M</given-names></name><name><surname>Shih</surname> <given-names>I</given-names></name><name><surname>Theodorescu</surname> <given-names>D</given-names></name><name><surname>Torbenson</surname> <given-names>MS</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name><name><surname>Wang</surname> <given-names>TL</given-names></name><name><surname>Wentzensen</surname> <given-names>N</given-names></name><name><surname>Wood</surname> <given-names>LD</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>McLendon</surname> <given-names>RE</given-names></name><name><surname>Bigner</surname> <given-names>DD</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Yan</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal</article-title><source>PNAS</source><volume>110</volume><fpage>6021</fpage><lpage>6026</lpage><pub-id pub-id-type="doi">10.1073/pnas.1303607110</pub-id><pub-id pub-id-type="pmid">23530248</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinde</surname> <given-names>I</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Detection and quantification of rare mutations with massively parallel sequencing</article-title><source>PNAS</source><volume>108</volume><fpage>9530</fpage><lpage>9535</lpage><pub-id pub-id-type="doi">10.1073/pnas.1105422108</pub-id><pub-id pub-id-type="pmid">21586637</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinde</surname> <given-names>I</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>FAST-SeqS: a simple and efficient method for the detection of aneuploidy by massively parallel sequencing</article-title><source>PLoS One</source><volume>7</volume><elocation-id>e41162</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0041162</pub-id><pub-id pub-id-type="pmid">22815955</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinde</surname> <given-names>I</given-names></name><name><surname>Munari</surname> <given-names>E</given-names></name><name><surname>Faraj</surname> <given-names>SF</given-names></name><name><surname>Hruban</surname> <given-names>RH</given-names></name><name><surname>Schoenberg</surname> <given-names>M</given-names></name><name><surname>Bivalacqua</surname> <given-names>T</given-names></name><name><surname>Allaf</surname> <given-names>M</given-names></name><name><surname>Springer</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Netto</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine</article-title><source>Cancer Research</source><volume>73</volume><fpage>7162</fpage><lpage>7167</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2498</pub-id><pub-id pub-id-type="pmid">24121487</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krüger</surname> <given-names>S</given-names></name><name><surname>Mess</surname> <given-names>F</given-names></name><name><surname>Böhle</surname> <given-names>A</given-names></name><name><surname>Feller</surname> <given-names>AC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder</article-title><source>International Journal of Oncology</source><volume>23</volume><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.3892/ijo.23.1.41</pub-id><pub-id pub-id-type="pmid">12792774</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname> <given-names>MN</given-names></name><name><surname>Wang</surname> <given-names>SM</given-names></name><name><surname>Chen</surname> <given-names>PC</given-names></name><name><surname>Chen</surname> <given-names>YY</given-names></name><name><surname>Wang</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk</article-title><source>JNCI Journal of the National Cancer Institute</source><volume>102</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1093/jnci/djp467</pub-id><pub-id pub-id-type="pmid">20026811</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>JY</given-names></name><name><surname>Kim</surname> <given-names>K</given-names></name><name><surname>Sung</surname> <given-names>HH</given-names></name><name><surname>Jeon</surname> <given-names>HG</given-names></name><name><surname>Jeong</surname> <given-names>BC</given-names></name><name><surname>Seo</surname> <given-names>SI</given-names></name><name><surname>Jeon</surname> <given-names>SS</given-names></name><name><surname>Lee</surname> <given-names>HM</given-names></name><name><surname>Choi</surname> <given-names>HY</given-names></name><name><surname>Kwon</surname> <given-names>GY</given-names></name><name><surname>Kim</surname> <given-names>KM</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Lim</surname> <given-names>HY</given-names></name><name><surname>Park</surname> <given-names>SH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Molecular characterization of urothelial carcinoma of the bladder and upper urinary tract</article-title><source>Translational Oncology</source><volume>11</volume><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.tranon.2017.10.008</pub-id><pub-id pub-id-type="pmid">29161613</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname> <given-names>AS</given-names></name><name><surname>Eckardt</surname> <given-names>KU</given-names></name><name><surname>Tsukamoto</surname> <given-names>Y</given-names></name><name><surname>Levin</surname> <given-names>A</given-names></name><name><surname>Coresh</surname> <given-names>J</given-names></name><name><surname>Rossert</surname> <given-names>J</given-names></name><name><surname>De Zeeuw</surname> <given-names>D</given-names></name><name><surname>Hostetter</surname> <given-names>TH</given-names></name><name><surname>Lameire</surname> <given-names>N</given-names></name><name><surname>Eknoyan</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)</article-title><source>Kidney International</source><volume>67</volume><fpage>2089</fpage><lpage>2100</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00365.x</pub-id><pub-id pub-id-type="pmid">15882252</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname> <given-names>AS</given-names></name><name><surname>Coresh</surname> <given-names>J</given-names></name><name><surname>Greene</surname> <given-names>T</given-names></name><name><surname>Stevens</surname> <given-names>LA</given-names></name><name><surname>Zhang</surname> <given-names>YL</given-names></name><name><surname>Hendriksen</surname> <given-names>S</given-names></name><name><surname>Kusek</surname> <given-names>JW</given-names></name><name><surname>Van Lente</surname> <given-names>F</given-names></name><collab>Chronic Kidney Disease Epidemiology Collaboration</collab></person-group><year iso-8601-date="2006">2006</year><article-title>Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate</article-title><source>Annals of Internal Medicine</source><volume>145</volume><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-145-4-200608150-00004</pub-id><pub-id pub-id-type="pmid">16908915</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>CC</given-names></name><name><surname>Chang</surname> <given-names>TH</given-names></name><name><surname>Wu</surname> <given-names>WJ</given-names></name><name><surname>Ke</surname> <given-names>HL</given-names></name><name><surname>Huang</surname> <given-names>SP</given-names></name><name><surname>Tsai</surname> <given-names>PC</given-names></name><name><surname>Chang</surname> <given-names>SJ</given-names></name><name><surname>Shen</surname> <given-names>JT</given-names></name><name><surname>Chou</surname> <given-names>YH</given-names></name><name><surname>Huang</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients</article-title><source>European Urology</source><volume>54</volume><fpage>1127</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2008.01.054</pub-id><pub-id pub-id-type="pmid">18243511</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>HH</given-names></name><name><surname>Ke</surname> <given-names>HL</given-names></name><name><surname>Huang</surname> <given-names>SP</given-names></name><name><surname>Wu</surname> <given-names>WJ</given-names></name><name><surname>Chen</surname> <given-names>YK</given-names></name><name><surname>Chang</surname> <given-names>LL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine</article-title><source>Urologic Oncology: Seminars and Original Investigations</source><volume>28</volume><fpage>597</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.urolonc.2008.12.008</pub-id><pub-id pub-id-type="pmid">19181545</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotan</surname> <given-names>Y</given-names></name><name><surname>Roehrborn</surname> <given-names>CG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses</article-title><source>Urology</source><volume>61</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/S0090-4295(02)02136-2</pub-id><pub-id pub-id-type="pmid">12559279</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGranahan</surname> <given-names>N</given-names></name><name><surname>Favero</surname> <given-names>F</given-names></name><name><surname>de Bruin</surname> <given-names>EC</given-names></name><name><surname>Birkbak</surname> <given-names>NJ</given-names></name><name><surname>Szallasi</surname> <given-names>Z</given-names></name><name><surname>Swanton</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Clonal status of actionable driver events and the timing of mutational processes in cancer evolution</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>283ra54</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa1408</pub-id><pub-id pub-id-type="pmid">25877892</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishriki</surname> <given-names>SF</given-names></name><name><surname>Nabi</surname> <given-names>G</given-names></name><name><surname>Cohen</surname> <given-names>NP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Diagnosis of urologic malignancies in patients with asymptomatic dipstick hematuria: prospective study with 13 years' follow-up</article-title><source>Urology</source><volume>71</volume><fpage>13</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2007.08.031</pub-id><pub-id pub-id-type="pmid">18242356</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname> <given-names>L</given-names></name><name><surname>Zheng</surname> <given-names>X</given-names></name><name><surname>Huang</surname> <given-names>HY</given-names></name><name><surname>Shapiro</surname> <given-names>E</given-names></name><name><surname>Lepor</surname> <given-names>H</given-names></name><name><surname>Cordon-Cardo</surname> <given-names>C</given-names></name><name><surname>Sun</surname> <given-names>TT</given-names></name><name><surname>Wu</surname> <given-names>XR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis</article-title><source>Journal of Clinical Investigation</source><volume>117</volume><fpage>314</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1172/JCI30062</pub-id><pub-id pub-id-type="pmid">17256055</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moonen</surname> <given-names>PM</given-names></name><name><surname>Merkx</surname> <given-names>GF</given-names></name><name><surname>Peelen</surname> <given-names>P</given-names></name><name><surname>Karthaus</surname> <given-names>HF</given-names></name><name><surname>Smeets</surname> <given-names>DF</given-names></name><name><surname>Witjes</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer</article-title><source>European Urology</source><volume>51</volume><fpage>1275</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2006.10.044</pub-id><pub-id pub-id-type="pmid">17084511</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriya</surname> <given-names>M</given-names></name><name><surname>Slade</surname> <given-names>N</given-names></name><name><surname>Brdar</surname> <given-names>B</given-names></name><name><surname>Medverec</surname> <given-names>Z</given-names></name><name><surname>Tomic</surname> <given-names>K</given-names></name><name><surname>Jelaković</surname> <given-names>B</given-names></name><name><surname>Wu</surname> <given-names>L</given-names></name><name><surname>Truong</surname> <given-names>S</given-names></name><name><surname>Fernandes</surname> <given-names>A</given-names></name><name><surname>Grollman</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>TP53 Mutational signature for aristolochic acid: an environmental carcinogen</article-title><source>International Journal of Cancer</source><volume>129</volume><fpage>1532</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1002/ijc.26077</pub-id><pub-id pub-id-type="pmid">21413016</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname> <given-names>TJ</given-names></name><name><surname>Qi</surname> <given-names>Y</given-names></name><name><surname>Xi</surname> <given-names>L</given-names></name><name><surname>Peng</surname> <given-names>B</given-names></name><name><surname>Kim</surname> <given-names>TB</given-names></name><name><surname>Ezzedine</surname> <given-names>NE</given-names></name><name><surname>Mosqueda</surname> <given-names>ME</given-names></name><name><surname>Guo</surname> <given-names>CC</given-names></name><name><surname>Czerniak</surname> <given-names>BA</given-names></name><name><surname>Ittmann</surname> <given-names>M</given-names></name><name><surname>Wheeler</surname> <given-names>DA</given-names></name><name><surname>Lerner</surname> <given-names>SP</given-names></name><name><surname>Matin</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comprehensive genomic characterization of upper tract urothelial carcinoma</article-title><source>European Urology</source><volume>72</volume><fpage>641</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2017.05.048</pub-id><pub-id pub-id-type="pmid">28601352</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>National Toxicology Program</collab></person-group><year iso-8601-date="2011">2011</year><article-title>Aristolochic acids</article-title><source>Report on Carcinogens : Carcinogen Profiles</source><volume>12</volume><fpage>45</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">21822318</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netto</surname> <given-names>GJ</given-names></name><name><surname>Epstein</surname> <given-names>JI</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Theranostic and prognostic biomarkers: genomic applications in urological malignancies</article-title><source>Pathology</source><volume>42</volume><fpage>384</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.3109/00313021003779145</pub-id><pub-id pub-id-type="pmid">20438413</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netto</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?</article-title><source>Nature Reviews Urology</source><volume>9</volume><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2011.193</pub-id><pub-id pub-id-type="pmid">22158597</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netto</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Clinical applications of recent molecular advances in urologic malignancies: no longer chasing a &quot;mirage&quot;?</article-title><source>Advances in Anatomic Pathology</source><volume>20</volume><fpage>175</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1097/PAP.0b013e3182863f80</pub-id><pub-id pub-id-type="pmid">23574774</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netto</surname> <given-names>GJ</given-names></name><name><surname>Tafe</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Emerging bladder cancer biomarkers and targets of therapy</article-title><source>Urologic Clinics of North America</source><volume>43</volume><fpage>63</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.ucl.2015.08.006</pub-id><pub-id pub-id-type="pmid">26614029</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>D</given-names></name><name><surname>Taheri</surname> <given-names>D</given-names></name><name><surname>Springer</surname> <given-names>S</given-names></name><name><surname>Cowan</surname> <given-names>M</given-names></name><name><surname>Guner</surname> <given-names>G</given-names></name><name><surname>Mendoza Rodriguez</surname> <given-names>MA</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Kinde</surname> <given-names>I</given-names></name><name><surname>VandenBussche</surname> <given-names>CJ</given-names></name><name><surname>Olson</surname> <given-names>MT</given-names></name><name><surname>Ricardo</surname> <given-names>BF</given-names></name><name><surname>Cunha</surname> <given-names>I</given-names></name><name><surname>Fujita</surname> <given-names>K</given-names></name><name><surname>Ertoy</surname> <given-names>D</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Bivalacqua</surname> <given-names>TJ</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Netto</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma</article-title><source>Virchows Archiv</source><volume>469</volume><fpage>427</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1007/s00428-016-2001-2</pub-id><pub-id pub-id-type="pmid">27520411</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>KM</given-names></name><name><surname>van der Vos</surname> <given-names>KE</given-names></name><name><surname>Smith</surname> <given-names>CG</given-names></name><name><surname>Mouliere</surname> <given-names>F</given-names></name><name><surname>Tsui</surname> <given-names>D</given-names></name><name><surname>Morris</surname> <given-names>J</given-names></name><name><surname>Chandrananda</surname> <given-names>D</given-names></name><name><surname>Marass</surname> <given-names>F</given-names></name><name><surname>van den Broek</surname> <given-names>D</given-names></name><name><surname>Neal</surname> <given-names>DE</given-names></name><name><surname>Gnanapragasam</surname> <given-names>VJ</given-names></name><name><surname>Forshew</surname> <given-names>T</given-names></name><name><surname>van Rhijn</surname> <given-names>BW</given-names></name><name><surname>Massie</surname> <given-names>CE</given-names></name><name><surname>Rosenfeld</surname> <given-names>N</given-names></name><name><surname>van der Heijden</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Association of plasma and urinary mutant dna with clinical outcomes in muscle invasive bladder cancer</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>5554</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-05623-3</pub-id><pub-id pub-id-type="pmid">28717136</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poon</surname> <given-names>SL</given-names></name><name><surname>Huang</surname> <given-names>MN</given-names></name><name><surname>Choo</surname> <given-names>Y</given-names></name><name><surname>McPherson</surname> <given-names>JR</given-names></name><name><surname>Yu</surname> <given-names>W</given-names></name><name><surname>Heng</surname> <given-names>HL</given-names></name><name><surname>Gan</surname> <given-names>A</given-names></name><name><surname>Myint</surname> <given-names>SS</given-names></name><name><surname>Siew</surname> <given-names>EY</given-names></name><name><surname>Ler</surname> <given-names>LD</given-names></name><name><surname>Ng</surname> <given-names>LG</given-names></name><name><surname>Weng</surname> <given-names>WH</given-names></name><name><surname>Chuang</surname> <given-names>CK</given-names></name><name><surname>Yuen</surname> <given-names>JS</given-names></name><name><surname>Pang</surname> <given-names>ST</given-names></name><name><surname>Tan</surname> <given-names>P</given-names></name><name><surname>Teh</surname> <given-names>BT</given-names></name><name><surname>Rozen</surname> <given-names>SG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutation signatures implicate aristolochic acid in bladder cancer development</article-title><source>Genome Medicine</source><volume>7</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-015-0161-3</pub-id><pub-id pub-id-type="pmid">26015808</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ralla</surname> <given-names>B</given-names></name><name><surname>Stephan</surname> <given-names>C</given-names></name><name><surname>Meller</surname> <given-names>S</given-names></name><name><surname>Dietrich</surname> <given-names>D</given-names></name><name><surname>Kristiansen</surname> <given-names>G</given-names></name><name><surname>Jung</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies</article-title><source>Critical Reviews in Clinical Laboratory Sciences</source><volume>51</volume><fpage>200</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.3109/10408363.2014.914888</pub-id><pub-id pub-id-type="pmid">24878357</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risques</surname> <given-names>RA</given-names></name><name><surname>Kennedy</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Aging and the rise of somatic cancer-associated mutations in normal tissues</article-title><source>PLOS Genetics</source><volume>14</volume><fpage>e1007108</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1007108</pub-id><pub-id pub-id-type="pmid">29300727</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez Pena</surname> <given-names>MDC</given-names></name><name><surname>Tregnago</surname> <given-names>AC</given-names></name><name><surname>Eich</surname> <given-names>ML</given-names></name><name><surname>Springer</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Taheri</surname> <given-names>D</given-names></name><name><surname>Ertoy</surname> <given-names>D</given-names></name><name><surname>Fujita</surname> <given-names>K</given-names></name><name><surname>Bezerra</surname> <given-names>SM</given-names></name><name><surname>Cunha</surname> <given-names>IW</given-names></name><name><surname>Raspollini</surname> <given-names>MR</given-names></name><name><surname>Yu</surname> <given-names>L</given-names></name><name><surname>Bivalacqua</surname> <given-names>TJ</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Netto</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder</article-title><source>Virchows Archiv</source><volume>471</volume><fpage>761</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1007/s00428-017-2164-5</pub-id><pub-id pub-id-type="pmid">28597078</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouprêt</surname> <given-names>M</given-names></name><name><surname>Babjuk</surname> <given-names>M</given-names></name><name><surname>Compérat</surname> <given-names>E</given-names></name><name><surname>Zigeuner</surname> <given-names>R</given-names></name><name><surname>Sylvester</surname> <given-names>RJ</given-names></name><name><surname>Burger</surname> <given-names>M</given-names></name><name><surname>Cowan</surname> <given-names>NC</given-names></name><name><surname>Böhle</surname> <given-names>A</given-names></name><name><surname>Van Rhijn</surname> <given-names>BW</given-names></name><name><surname>Kaasinen</surname> <given-names>E</given-names></name><name><surname>Palou</surname> <given-names>J</given-names></name><name><surname>Shariat</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 Update</article-title><source>European Urology</source><volume>68</volume><fpage>868</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2015.06.044</pub-id><pub-id pub-id-type="pmid">26188393</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkis</surname> <given-names>AS</given-names></name><name><surname>Dalbagni</surname> <given-names>G</given-names></name><name><surname>Cordon-Cardo</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>ZF</given-names></name><name><surname>Sheinfeld</surname> <given-names>J</given-names></name><name><surname>Fair</surname> <given-names>WR</given-names></name><name><surname>Herr</surname> <given-names>HW</given-names></name><name><surname>Reuter</surname> <given-names>VE</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression</article-title><source>JNCI Journal of the National Cancer Institute</source><volume>85</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1093/jnci/85.1.53</pub-id><pub-id pub-id-type="pmid">7677935</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkis</surname> <given-names>AS</given-names></name><name><surname>Dalbagni</surname> <given-names>G</given-names></name><name><surname>Cordon-Cardo</surname> <given-names>C</given-names></name><name><surname>Melamed</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>ZF</given-names></name><name><surname>Sheinfeld</surname> <given-names>J</given-names></name><name><surname>Fair</surname> <given-names>WR</given-names></name><name><surname>Herr</surname> <given-names>HW</given-names></name><name><surname>Reuter</surname> <given-names>VE</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder</article-title><source>The Journal of Urology</source><volume>152</volume><fpage>388</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(17)32745-3</pub-id><pub-id pub-id-type="pmid">8015077</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkis</surname> <given-names>AS</given-names></name><name><surname>Bajorin</surname> <given-names>DF</given-names></name><name><surname>Reuter</surname> <given-names>VE</given-names></name><name><surname>Herr</surname> <given-names>HW</given-names></name><name><surname>Netto</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>ZF</given-names></name><name><surname>Schultz</surname> <given-names>PK</given-names></name><name><surname>Cordon-Cardo</surname> <given-names>C</given-names></name><name><surname>Scher</surname> <given-names>HI</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC</article-title><source>Journal of Clinical Oncology</source><volume>13</volume><fpage>1384</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1200/JCO.1995.13.6.1384</pub-id><pub-id pub-id-type="pmid">7751883</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarosdy</surname> <given-names>MF</given-names></name><name><surname>Kahn</surname> <given-names>PR</given-names></name><name><surname>Ziffer</surname> <given-names>MD</given-names></name><name><surname>Love</surname> <given-names>WR</given-names></name><name><surname>Barkin</surname> <given-names>J</given-names></name><name><surname>Abara</surname> <given-names>EO</given-names></name><name><surname>Jansz</surname> <given-names>K</given-names></name><name><surname>Bridge</surname> <given-names>JA</given-names></name><name><surname>Johansson</surname> <given-names>SL</given-names></name><name><surname>Persons</surname> <given-names>DL</given-names></name><name><surname>Gibson</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria</article-title><source>The Journal of Urology</source><volume>176</volume><fpage>44</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(06)00576-3</pub-id><pub-id pub-id-type="pmid">16753364</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname> <given-names>GA</given-names></name><name><surname>Laughlin</surname> <given-names>TS</given-names></name><name><surname>Rothberg</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma</article-title><source>Modern Pathology</source><volume>27</volume><fpage>516</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2013.167</pub-id><pub-id pub-id-type="pmid">24030752</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serizawa</surname> <given-names>RR</given-names></name><name><surname>Ralfkiaer</surname> <given-names>U</given-names></name><name><surname>Steven</surname> <given-names>K</given-names></name><name><surname>Lam</surname> <given-names>GW</given-names></name><name><surname>Schmiedel</surname> <given-names>S</given-names></name><name><surname>Schüz</surname> <given-names>J</given-names></name><name><surname>Hansen</surname> <given-names>AB</given-names></name><name><surname>Horn</surname> <given-names>T</given-names></name><name><surname>Guldberg</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events</article-title><source>International Journal of Cancer</source><volume>129</volume><fpage>78</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1002/ijc.25651</pub-id><pub-id pub-id-type="pmid">20824703</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sfakianos</surname> <given-names>JP</given-names></name><name><surname>Cha</surname> <given-names>EK</given-names></name><name><surname>Iyer</surname> <given-names>G</given-names></name><name><surname>Scott</surname> <given-names>SN</given-names></name><name><surname>Zabor</surname> <given-names>EC</given-names></name><name><surname>Shah</surname> <given-names>RH</given-names></name><name><surname>Ren</surname> <given-names>Q</given-names></name><name><surname>Bagrodia</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>PH</given-names></name><name><surname>Hakimi</surname> <given-names>AA</given-names></name><name><surname>Ostrovnaya</surname> <given-names>I</given-names></name><name><surname>Ramirez</surname> <given-names>R</given-names></name><name><surname>Hanrahan</surname> <given-names>AJ</given-names></name><name><surname>Desai</surname> <given-names>NB</given-names></name><name><surname>Sun</surname> <given-names>A</given-names></name><name><surname>Pinciroli</surname> <given-names>P</given-names></name><name><surname>Rosenberg</surname> <given-names>JE</given-names></name><name><surname>Dalbagni</surname> <given-names>G</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name><name><surname>Bajorin</surname> <given-names>DF</given-names></name><name><surname>Reuter</surname> <given-names>VE</given-names></name><name><surname>Berger</surname> <given-names>MF</given-names></name><name><surname>Bochner</surname> <given-names>BH</given-names></name><name><surname>Al-Ahmadie</surname> <given-names>HA</given-names></name><name><surname>Solit</surname> <given-names>DB</given-names></name><name><surname>Coleman</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genomic characterization of upper tract urothelial carcinoma</article-title><source>European Urology</source><volume>68</volume><fpage>970</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2015.07.039</pub-id><pub-id pub-id-type="pmid">26278805</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shariat</surname> <given-names>SF</given-names></name><name><surname>Favaretto</surname> <given-names>RL</given-names></name><name><surname>Gupta</surname> <given-names>A</given-names></name><name><surname>Fritsche</surname> <given-names>HM</given-names></name><name><surname>Matsumoto</surname> <given-names>K</given-names></name><name><surname>Kassouf</surname> <given-names>W</given-names></name><name><surname>Walton</surname> <given-names>TJ</given-names></name><name><surname>Tritschler</surname> <given-names>S</given-names></name><name><surname>Baba</surname> <given-names>S</given-names></name><name><surname>Matsushita</surname> <given-names>K</given-names></name><name><surname>Bastian</surname> <given-names>PJ</given-names></name><name><surname>Martínez-Salamanca</surname> <given-names>JI</given-names></name><name><surname>Seitz</surname> <given-names>C</given-names></name><name><surname>Pycha</surname> <given-names>A</given-names></name><name><surname>Otto</surname> <given-names>W</given-names></name><name><surname>Karakiewicz</surname> <given-names>PI</given-names></name><name><surname>Ficarra</surname> <given-names>V</given-names></name><name><surname>Novara</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma</article-title><source>World Journal of Urology</source><volume>29</volume><fpage>481</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1007/s00345-010-0594-7</pub-id><pub-id pub-id-type="pmid">20886219</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidransky</surname> <given-names>D</given-names></name><name><surname>Von Eschenbach</surname> <given-names>A</given-names></name><name><surname>Tsai</surname> <given-names>YC</given-names></name><name><surname>Jones</surname> <given-names>P</given-names></name><name><surname>Summerhayes</surname> <given-names>I</given-names></name><name><surname>Marshall</surname> <given-names>F</given-names></name><name><surname>Paul</surname> <given-names>M</given-names></name><name><surname>Green</surname> <given-names>P</given-names></name><name><surname>Hamilton</surname> <given-names>SR</given-names></name><name><surname>Frost</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Identification of p53 gene mutations in bladder cancers and urine samples</article-title><source>Science</source><volume>252</volume><fpage>706</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1126/science.2024123</pub-id><pub-id pub-id-type="pmid">2024123</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname> <given-names>RL</given-names></name><name><surname>Miller</surname> <given-names>KD</given-names></name><name><surname>Jemal</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cancer Statistics, 2017</article-title><source>CA: A Cancer Journal for Clinicians</source><volume>67</volume><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3322/caac.21387</pub-id><pub-id pub-id-type="pmid">28055103</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skacel</surname> <given-names>M</given-names></name><name><surname>Fahmy</surname> <given-names>M</given-names></name><name><surname>Brainard</surname> <given-names>JA</given-names></name><name><surname>Pettay</surname> <given-names>JD</given-names></name><name><surname>Biscotti</surname> <given-names>CV</given-names></name><name><surname>Liou</surname> <given-names>LS</given-names></name><name><surname>Procop</surname> <given-names>GW</given-names></name><name><surname>Jones</surname> <given-names>JS</given-names></name><name><surname>Ulchaker</surname> <given-names>J</given-names></name><name><surname>Zippe</surname> <given-names>CD</given-names></name><name><surname>Tubbs</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology</article-title><source>The Journal of Urology</source><volume>169</volume><fpage>2101</fpage><lpage>2105</lpage><pub-id pub-id-type="doi">10.1097/01.ju.0000066842.45464.cc</pub-id><pub-id pub-id-type="pmid">12771727</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soria</surname> <given-names>F</given-names></name><name><surname>Shariat</surname> <given-names>SF</given-names></name><name><surname>Lerner</surname> <given-names>SP</given-names></name><name><surname>Fritsche</surname> <given-names>HM</given-names></name><name><surname>Rink</surname> <given-names>M</given-names></name><name><surname>Kassouf</surname> <given-names>W</given-names></name><name><surname>Spiess</surname> <given-names>PE</given-names></name><name><surname>Lotan</surname> <given-names>Y</given-names></name><name><surname>Ye</surname> <given-names>D</given-names></name><name><surname>Fernández</surname> <given-names>MI</given-names></name><name><surname>Kikuchi</surname> <given-names>E</given-names></name><name><surname>Chade</surname> <given-names>DC</given-names></name><name><surname>Babjuk</surname> <given-names>M</given-names></name><name><surname>Grollman</surname> <given-names>AP</given-names></name><name><surname>Thalmann</surname> <given-names>GN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)</article-title><source>World Journal of Urology</source><volume>35</volume><fpage>379</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1007/s00345-016-1928-x</pub-id><pub-id pub-id-type="pmid">27604375</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Springer</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Dal Molin</surname> <given-names>M</given-names></name><name><surname>Masica</surname> <given-names>DL</given-names></name><name><surname>Jiao</surname> <given-names>Y</given-names></name><name><surname>Kinde</surname> <given-names>I</given-names></name><name><surname>Blackford</surname> <given-names>A</given-names></name><name><surname>Raman</surname> <given-names>SP</given-names></name><name><surname>Wolfgang</surname> <given-names>CL</given-names></name><name><surname>Tomita</surname> <given-names>T</given-names></name><name><surname>Niknafs</surname> <given-names>N</given-names></name><name><surname>Douville</surname> <given-names>C</given-names></name><name><surname>Ptak</surname> <given-names>J</given-names></name><name><surname>Dobbyn</surname> <given-names>L</given-names></name><name><surname>Allen</surname> <given-names>PJ</given-names></name><name><surname>Klimstra</surname> <given-names>DS</given-names></name><name><surname>Schattner</surname> <given-names>MA</given-names></name><name><surname>Schmidt</surname> <given-names>CM</given-names></name><name><surname>Yip-Schneider</surname> <given-names>M</given-names></name><name><surname>Cummings</surname> <given-names>OW</given-names></name><name><surname>Brand</surname> <given-names>RE</given-names></name><name><surname>Zeh</surname> <given-names>HJ</given-names></name><name><surname>Singhi</surname> <given-names>AD</given-names></name><name><surname>Scarpa</surname> <given-names>A</given-names></name><name><surname>Salvia</surname> <given-names>R</given-names></name><name><surname>Malleo</surname> <given-names>G</given-names></name><name><surname>Zamboni</surname> <given-names>G</given-names></name><name><surname>Falconi</surname> <given-names>M</given-names></name><name><surname>Jang</surname> <given-names>JY</given-names></name><name><surname>Kim</surname> <given-names>SW</given-names></name><name><surname>Kwon</surname> <given-names>W</given-names></name><name><surname>Hong</surname> <given-names>SM</given-names></name><name><surname>Song</surname> <given-names>KB</given-names></name><name><surname>Kim</surname> <given-names>SC</given-names></name><name><surname>Swan</surname> <given-names>N</given-names></name><name><surname>Murphy</surname> <given-names>J</given-names></name><name><surname>Geoghegan</surname> <given-names>J</given-names></name><name><surname>Brugge</surname> <given-names>W</given-names></name><name><surname>Fernandez-Del Castillo</surname> <given-names>C</given-names></name><name><surname>Mino-Kenudson</surname> <given-names>M</given-names></name><name><surname>Schulick</surname> <given-names>R</given-names></name><name><surname>Edil</surname> <given-names>BH</given-names></name><name><surname>Adsay</surname> <given-names>V</given-names></name><name><surname>Paulino</surname> <given-names>J</given-names></name><name><surname>van Hooft</surname> <given-names>J</given-names></name><name><surname>Yachida</surname> <given-names>S</given-names></name><name><surname>Nara</surname> <given-names>S</given-names></name><name><surname>Hiraoka</surname> <given-names>N</given-names></name><name><surname>Yamao</surname> <given-names>K</given-names></name><name><surname>Hijioka</surname> <given-names>S</given-names></name><name><surname>van der Merwe</surname> <given-names>S</given-names></name><name><surname>Goggins</surname> <given-names>M</given-names></name><name><surname>Canto</surname> <given-names>MI</given-names></name><name><surname>Ahuja</surname> <given-names>N</given-names></name><name><surname>Hirose</surname> <given-names>K</given-names></name><name><surname>Makary</surname> <given-names>M</given-names></name><name><surname>Weiss</surname> <given-names>MJ</given-names></name><name><surname>Cameron</surname> <given-names>J</given-names></name><name><surname>Pittman</surname> <given-names>M</given-names></name><name><surname>Eshleman</surname> <given-names>JR</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Karchin</surname> <given-names>R</given-names></name><name><surname>Hruban</surname> <given-names>RH</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Lennon</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A combination of molecular markers and clinical features improve the classification of pancreatic cysts</article-title><source>Gastroenterology</source><volume>149</volume><fpage>1501</fpage><lpage>1510</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.07.041</pub-id><pub-id pub-id-type="pmid">26253305</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname> <given-names>JL</given-names></name><name><surname>Theodorescu</surname> <given-names>D</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Cech</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers</article-title><source>Genes &amp; Development</source><volume>29</volume><fpage>2219</fpage><lpage>2224</lpage><pub-id pub-id-type="doi">10.1101/gad.269498.115</pub-id><pub-id pub-id-type="pmid">26515115</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Taiwan Cancer Registry</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Bureau of Health Promotion, Dept. of Health, Taiwan. The incidence of renal pelvic and ureteral tumor in Taiwan</article-title><source>Taiwan Cancer Registry</source><ext-link ext-link-type="uri" xlink:href="https://cris.bhp.doh.gov.tw/pagepub/Home.aspx?itemNo=cr.q.10">https://cris.bhp.doh.gov.tw/pagepub/Home.aspx?itemNo=cr.q.10</ext-link><date-in-citation iso-8601-date="2017-08-14">August 14, 2017</date-in-citation></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Togneri</surname> <given-names>FS</given-names></name><name><surname>Ward</surname> <given-names>DG</given-names></name><name><surname>Foster</surname> <given-names>JM</given-names></name><name><surname>Devall</surname> <given-names>AJ</given-names></name><name><surname>Wojtowicz</surname> <given-names>P</given-names></name><name><surname>Alyas</surname> <given-names>S</given-names></name><name><surname>Vasques</surname> <given-names>FR</given-names></name><name><surname>Oumie</surname> <given-names>A</given-names></name><name><surname>James</surname> <given-names>ND</given-names></name><name><surname>Cheng</surname> <given-names>KK</given-names></name><name><surname>Zeegers</surname> <given-names>MP</given-names></name><name><surname>Deshmukh</surname> <given-names>N</given-names></name><name><surname>O'Sullivan</surname> <given-names>B</given-names></name><name><surname>Taniere</surname> <given-names>P</given-names></name><name><surname>Spink</surname> <given-names>KG</given-names></name><name><surname>McMullan</surname> <given-names>DJ</given-names></name><name><surname>Griffiths</surname> <given-names>M</given-names></name><name><surname>Bryan</surname> <given-names>RT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA</article-title><source>European Journal of Human Genetics</source><volume>24</volume><fpage>1167</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2015.281</pub-id><pub-id pub-id-type="pmid">26757983</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Digital PCR</article-title><source>PNAS</source><volume>96</volume><fpage>9236</fpage><lpage>9241</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.16.9236</pub-id><pub-id pub-id-type="pmid">10430926</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Velculescu</surname> <given-names>VE</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cancer genome landscapes</article-title><source>Science</source><volume>339</volume><fpage>1546</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1126/science.1235122</pub-id><pub-id pub-id-type="pmid">23539594</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Ge</surname> <given-names>N</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Yuan</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Kong</surname> <given-names>F</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Ren</surname> <given-names>H</given-names></name><name><surname>Yan</surname> <given-names>K</given-names></name><name><surname>Hu</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>Z</given-names></name><name><surname>Björkholm</surname> <given-names>M</given-names></name><name><surname>Fan</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Xu</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR</article-title><source>Oncotarget</source><volume>5</volume><fpage>12428</fpage><lpage>12439</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2660</pub-id><pub-id pub-id-type="pmid">25474136</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Springer</surname> <given-names>S</given-names></name><name><surname>Mulvey</surname> <given-names>CL</given-names></name><name><surname>Silliman</surname> <given-names>N</given-names></name><name><surname>Schaefer</surname> <given-names>J</given-names></name><name><surname>Sausen</surname> <given-names>M</given-names></name><name><surname>James</surname> <given-names>N</given-names></name><name><surname>Rettig</surname> <given-names>EM</given-names></name><name><surname>Guo</surname> <given-names>T</given-names></name><name><surname>Pickering</surname> <given-names>CR</given-names></name><name><surname>Bishop</surname> <given-names>JA</given-names></name><name><surname>Chung</surname> <given-names>CH</given-names></name><name><surname>Califano</surname> <given-names>JA</given-names></name><name><surname>Eisele</surname> <given-names>DW</given-names></name><name><surname>Fakhry</surname> <given-names>C</given-names></name><name><surname>Gourin</surname> <given-names>CG</given-names></name><name><surname>Ha</surname> <given-names>PK</given-names></name><name><surname>Kang</surname> <given-names>H</given-names></name><name><surname>Kiess</surname> <given-names>A</given-names></name><name><surname>Koch</surname> <given-names>WM</given-names></name><name><surname>Myers</surname> <given-names>JN</given-names></name><name><surname>Quon</surname> <given-names>H</given-names></name><name><surname>Richmon</surname> <given-names>JD</given-names></name><name><surname>Sidransky</surname> <given-names>D</given-names></name><name><surname>Tufano</surname> <given-names>RP</given-names></name><name><surname>Westra</surname> <given-names>WH</given-names></name><name><surname>Bettegowda</surname> <given-names>C</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Agrawal</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>293ra104</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa8507</pub-id><pub-id pub-id-type="pmid">26109104</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Springer</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>McMahon</surname> <given-names>KW</given-names></name><name><surname>Kinde</surname> <given-names>I</given-names></name><name><surname>Dobbyn</surname> <given-names>L</given-names></name><name><surname>Ptak</surname> <given-names>J</given-names></name><name><surname>Brem</surname> <given-names>H</given-names></name><name><surname>Chaichana</surname> <given-names>K</given-names></name><name><surname>Gallia</surname> <given-names>GL</given-names></name><name><surname>Gokaslan</surname> <given-names>ZL</given-names></name><name><surname>Groves</surname> <given-names>ML</given-names></name><name><surname>Jallo</surname> <given-names>GI</given-names></name><name><surname>Lim</surname> <given-names>M</given-names></name><name><surname>Olivi</surname> <given-names>A</given-names></name><name><surname>Quinones-Hinojosa</surname> <given-names>A</given-names></name><name><surname>Rigamonti</surname> <given-names>D</given-names></name><name><surname>Riggins</surname> <given-names>GJ</given-names></name><name><surname>Sciubba</surname> <given-names>DM</given-names></name><name><surname>Weingart</surname> <given-names>JD</given-names></name><name><surname>Wolinsky</surname> <given-names>JP</given-names></name><name><surname>Ye</surname> <given-names>X</given-names></name><name><surname>Oba-Shinjo</surname> <given-names>SM</given-names></name><name><surname>Marie</surname> <given-names>SK</given-names></name><name><surname>Holdhoff</surname> <given-names>M</given-names></name><name><surname>Agrawal</surname> <given-names>N</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name><name><surname>Bettegowda</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord</article-title><source>PNAS</source><volume>112</volume><fpage>9704</fpage><lpage>9709</lpage><pub-id pub-id-type="doi">10.1073/pnas.1511694112</pub-id><pub-id pub-id-type="pmid">26195750</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Sundfeldt</surname> <given-names>K</given-names></name><name><surname>Mateoiu</surname> <given-names>C</given-names></name><name><surname>Shih</surname> <given-names>I</given-names></name><name><surname>Kurman</surname> <given-names>RJ</given-names></name><name><surname>Schaefer</surname> <given-names>J</given-names></name><name><surname>Silliman</surname> <given-names>N</given-names></name><name><surname>Kinde</surname> <given-names>I</given-names></name><name><surname>Springer</surname> <given-names>S</given-names></name><name><surname>Foote</surname> <given-names>M</given-names></name><name><surname>Kristjansdottir</surname> <given-names>B</given-names></name><name><surname>James</surname> <given-names>N</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Papadopoulos</surname> <given-names>N</given-names></name><name><surname>Diaz</surname> <given-names>LA</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Diagnostic potential of tumor DNA from ovarian cyst fluid</article-title><source>eLife</source><volume>5</volume><elocation-id>e15175</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.15175</pub-id><pub-id pub-id-type="pmid">27421040</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wein</surname> <given-names>AJ</given-names></name><name><surname>Kavoussi</surname> <given-names>LR</given-names></name><name><surname>Novick</surname> <given-names>AC</given-names></name><name><surname>Partin</surname> <given-names>AW</given-names></name><name><surname>Peters</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2012">2012</year><source>Campbell-Walsh Urology</source><edition>10th</edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Elsevier/Saunders</publisher-name><pub-id pub-id-type="isbn">9781416069119</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>XR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Urothelial tumorigenesis: a tale of divergent pathways</article-title><source>Nature Reviews Cancer</source><volume>5</volume><fpage>713</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1038/nrc1697</pub-id><pub-id pub-id-type="pmid">16110317</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yafi</surname> <given-names>FA</given-names></name><name><surname>Brimo</surname> <given-names>F</given-names></name><name><surname>Steinberg</surname> <given-names>J</given-names></name><name><surname>Aprikian</surname> <given-names>AG</given-names></name><name><surname>Tanguay</surname> <given-names>S</given-names></name><name><surname>Kassouf</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer</article-title><source>Urologic Oncology: Seminars and Original Investigations</source><volume>33</volume><fpage>66.e25</fpage><lpage>66.e31</lpage><pub-id pub-id-type="doi">10.1016/j.urolonc.2014.06.008</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>MH</given-names></name><name><surname>Chen</surname> <given-names>KK</given-names></name><name><surname>Yen</surname> <given-names>CC</given-names></name><name><surname>Wang</surname> <given-names>WS</given-names></name><name><surname>Chang</surname> <given-names>YH</given-names></name><name><surname>Huang</surname> <given-names>WJ</given-names></name><name><surname>Fan</surname> <given-names>FS</given-names></name><name><surname>Chiou</surname> <given-names>TJ</given-names></name><name><surname>Liu</surname> <given-names>JH</given-names></name><name><surname>Chen</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan</article-title><source>Urology</source><volume>59</volume><fpage>681</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1016/S0090-4295(02)01529-7</pub-id><pub-id pub-id-type="pmid">11992840</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Ge</surname> <given-names>N</given-names></name><name><surname>Kong</surname> <given-names>F</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Björkholm</surname> <given-names>M</given-names></name><name><surname>Fan</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients</article-title><source>Oncotarget</source><volume>7</volume><fpage>25826</fpage><lpage>25835</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8404</pub-id><pub-id pub-id-type="pmid">27029078</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname> <given-names>BH</given-names></name><name><surname>Rosenquist</surname> <given-names>TA</given-names></name><name><surname>Sidorenko</surname> <given-names>V</given-names></name><name><surname>Iden</surname> <given-names>CR</given-names></name><name><surname>Chen</surname> <given-names>CH</given-names></name><name><surname>Pu</surname> <given-names>YS</given-names></name><name><surname>Bonala</surname> <given-names>R</given-names></name><name><surname>Johnson</surname> <given-names>F</given-names></name><name><surname>Dickman</surname> <given-names>KG</given-names></name><name><surname>Grollman</surname> <given-names>AP</given-names></name><name><surname>Turesky</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry</article-title><source>Chemical Research in Toxicology</source><volume>25</volume><fpage>1119</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1021/tx3000889</pub-id><pub-id pub-id-type="pmid">22515372</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>ML</given-names></name><name><surname>Rosenthal</surname> <given-names>DL</given-names></name><name><surname>VandenBussche</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The cytomorphological features of low-grade urothelial neoplasms vary by specimen type</article-title><source>Cancer Cytopathology</source><volume>124</volume><fpage>552</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1002/cncy.21716</pub-id><pub-id pub-id-type="pmid">27019161</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.32143.033</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Levine</surname><given-names>Ross L</given-names></name><role>Reviewing Editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Non-invasive detection of bladder cancer through the analysis of driver gene mutations and aneuploidy&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by Ross Levine as Reviewing Editor (and one of the reviewers) and Charles Sawyers as the Senior Editor.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>In summary, in the two manuscripts the authors develop a non-invasive molecular test called UroSEEK to analyze DNA from urinary CELLS shed into the urine. UroSEEK combines three assessments including mutations from exons in 11 genes, TERT mutations, and aneuploidy. UroSEEK has the potential to augment the sensitivity of routine cytology for the detection of cancer in patients with bladder cancer and upper tract urothelial carcinomas. For the bladder study, they looked at two cohorts, one with hematuria and the second with previous bladder cancer history at risk for new bladder cancers. For the urothelial study, this included 56 subjects with urothelial cancer. For each cohort, they used the same 188 control urine specimens from healthy subjects as negative controls. The main conclusion from these studies is the same – urinary cell mutation testing has potential to detect urothelial and bladder cancers. As such, we think it is best to combine these papers into a single report, which would be of broad interest to the field.</p><p>Essential Revisions:</p><p>1) There is significant overlap between these two manuscripts, and reading these separately does not add value to either one's conclusion, especially in the same journal issue of <italic>eLife</italic>. The clinical and diagnostics audience for urothelial and bladder cancer is the same. While the clinical cohorts are different, the genes, methods, controls, and disease (based on their common mutation assessment with URoSEEK) are identical. The written methods are identical. The message is the same – urinary cell mutation testing has potential to detect urothelial and bladder cancers.</p><p>2) The issue of how this approach compares to cystoscopy is a major one and is not thoughtfully discussed. If both tests are similar in cost, and cystoscopy is more invasive but definitive, will patients and payers want to use an equally costly non-invasive test vs the more definitive test? How would the authors propose to use this as part of the diagnostic workup and can the impact be modeled in terms of costs, # procedures, etc.? Would add value.</p><p>3) The lack of specificity, particularly with respect to positive genetic data in 1) patients without cancer and 2) in patients who previously had cancer and did not recur, is a substantive issue. Can this be improved? Are there ways to deal with this issue in terms of proposing a diagnostic approach? On this note, the methods/assay used have not been thoroughly vetted for sensitivity, specificity, limits of detection and reproducibility for a clinical assay, typically done with serial dilutions and replicates. The authors indicate that one reason for false negatives was due to discordant mutations on the gene panel and the tumor. Another reason could be the assay's limits of detection. While this has not been completed, nonetheless, it does not significantly diminish the conclusion from these studies that urinary cell mutation testing could augment cytology.</p><p>4) Have the authors modeled whether including more, or less than 11 genes + TERT/aneuploidy, would impact performance of the test? Are there ways to improve the design to improve performance?</p><p>5) Why did the authors separate these assays especially that the three assays that make up UroSEEK can be combined in one NGS platform (examples include assays developed by Foundation Medicine, MSK-IMPACT, Oncomine panel, etc.) that can provide more comprehensive genetic analysis on many more genes including mutations and copy number alterations. Some of the currently available NSG platforms can also utilize cfDNA.</p><p>The list of genes in the assay, while includes some of the very commonly mutated genes in bladder cancer, it leaves out other genes that are both relevant and common including for example ARID1A, KDM6A, CDKN1A, STAG2, MLL2/MLL3, etc. Including such genes would very likely improve the assay.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.32143.034</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential Revisions:</p></disp-quote><p><italic>1) There is significant overlap between these two manuscripts, and reading these separately does not add value to either one's conclusion, especially in the same journal issue of</italic> eLife<italic>. The clinical and diagnostics audience for urothelial and bladder cancer is the same. While the clinical cohorts are different, the genes, methods, controls, and disease (based on their common mutation assessment with URoSEEK) are identical. The written methods are identical. The message is the same – urinary cell mutation testing has potential to detect urothelial and bladder cancers.</italic> </p><p>The two manuscripts have been integrated into a single paper as requested.</p><disp-quote content-type="editor-comment"><p>2) The issue of how this approach compares to cystoscopy is a major one and is not thoughtfully discussed. If both tests are similar in cost, and cystoscopy is more invasive but definitive, will patients and payers want to use an equally costly non-invasive test vs the more definitive test? How would the authors propose to use this as part of the diagnostic workup and can the impact be modeled in terms of costs, # procedures, etc.? Would add value.</p></disp-quote><p>This is an important point, and we appreciate the reviewer's bringing it up. Cystoscopy is definitely definitive but is invasive and always associated with pain and inconvenience and occasionally associated with side effects such as infection, bleeding, urethral stenosis, etc. The procedure also requires skilled professionals to perform it. As the great majority of patients in some screening settings (e.g., hematuria) do not have cancer, these issues are precisely those that inspired our study. It is widely agreed that a non-invasive test that could be used to screen patients in such settings could minimize the need for cystoscopy and its unintended consequences.</p><p>The cost of cystoscopy is up to $3200, not including the cost of the pathology of biopsies. The cost of ureteroscopy is similar. We envision that the cost of UroSEEK plus cytology would be &lt;$750 when implemented in a commercial setting, using savings afforded by economy-of scale. We anticipate that &gt;90% of patients with hematuria who would otherwise undergo cystoscopy could be spared this procedure on the basis of a negative UroSEEK test The entire cost savings, integrated over all patients, would therefore be considerable: for every 100 patients evaluated, up to $200,000 would be saved (assuming UroSEEK plus cytology in all patients plus cystoscopy in 5% of the patients who test positive with UroSEEK). This translates to many millions of dollars in the U.S. annually, and does not include the cost of follow-ups for the side effects of cystoscopy when performed. These issues are now briefly discussed at the end of the revised Discussion.</p><disp-quote content-type="editor-comment"><p>3) The lack of specificity, particularly with respect to positive genetic data in 1) patients without cancer and 2) in patients who previously had cancer and did not recur, is a substantive issue. Can this be improved? Are there ways to deal with this issue in terms of proposing a diagnostic approach?</p></disp-quote><p>We agree with the reviewers that specificity is important, but there are two kinds of specificity. Technical specificity can be assessed from the evaluation of the test in DNA from totally normal individuals, such as DNA from normal WBCs. The technical specificity of UroSEEK is very high, over 99%, as reported in the manuscript. Biological specificity is different and reflects the cohorts studied. In urines from normal individuals (without any hematuria, for example), the specificity is as high as in as in normal WBCs (&gt;99%). As noted in the manuscript, though, this specificity is not as high in other cohorts. In the Discussion, this issue is discussed at length. For example, the 6.5% false positives in BC early detection cohort could be related to a lead time ahead of “clinical” detection. The follow-up period for many of patients was only one year, and cystoscopy was not performed in every patient as per current standards. The same issue could lead to apparently false positive results in the surveillance cohort, in which patients are at much higher risk for cancer than in the early detection cohorts. We will attempt to address such possibilities in future prospective studies that we are now planning where a longer follow up (e.g. 3 years minimum) should be helpful. False positives are not unique to our study; they have been observed in all other molecular assays for bladder cancer, including those that are FDA- approved. Even assuming that none of the false positives are due to as yet undetected cancers, the positive predictive values and negative predictive values in the early detection cohorts is considerably above what has been required for FDA-approval of diagnostic tests in general.</p><disp-quote content-type="editor-comment"><p>On this note, the methods/assay used have not been thoroughly vetted for sensitivity, specificity, limits of detection and reproducibility for a clinical assay, typically done with serial dilutions and replicates. The authors indicate that one reason for false negatives was due to discordant mutations on the gene panel and the tumor. Another reason could be the assay's limits of detection. While this has not been completed, nonetheless, it does not significantly diminish the conclusion from these studies that urinary cell mutation testing could augment cytology.</p></disp-quote><p>We appreciate the reviewers’ view that such detailed vetting is not critical for the conclusions made in this manuscript. But we would like to highlight several pieces of data that address this point. The reproducibility of the test has been exhaustively examined, because tests were scored positive <italic>if and only if</italic> an independent assay of DNA from the same urine sample was also positive. Moreover, the coefficients of variation of the duplicates were high, as noted in the table below (which can easily be recalculated by readers using the data recorded in the Supplementary files, wherein the results of each replicate are specified). We note that the CVs are relatively low even when the MAFs are low, meaning that there are only a few molecules present, helping to establish technical sensitivity (limit of sensitivity).</p><p>UroSEEK requires no complex molecular biological manipulations of DNA; it simply uses PCR of DNA purified from the urine. Thus, many of the issues that are faced by other next generation sequencing technologies, such as those involved in end-polishing of DNA, ligations, and captures, are avoided. The reproducibility and sensitivity of SafeSeqS, which is the basis for UroSEEK, has been previously documented in the original paper (Kinde et al., Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A, 108(23), 9530-9535).</p><p>Finally, we are in the process of licensing UroSEEK to a small start-up company that was founded by some of the senior authors of this study. As part of their due diligence and preparation for an upcoming clinical trial of UroSEEK based on the results reported in our manuscript, they have prepared a Clinical Laboratory Improvement Amendment (CLIA) report. Though the report cannot be made public, it provides additional evidence of the reproducibility of UroSEEK in a completely different laboratory.</p><p><table-wrap id="inlinetable2" position="anchor"><table frame="hsides" rules="groups"><tbody><tr><td valign="bottom"/><td colspan="4" valign="bottom">CV (SD/Mean*100)</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">Mutation Group (classified by MAF)</td><td valign="bottom">All</td><td valign="bottom">&gt;10%</td><td valign="bottom">&gt;5%</td><td valign="bottom">&gt;2%</td><td valign="bottom">&gt;1%</td><td valign="bottom">&gt;0.5%</td><td valign="bottom">&lt;0.5%</td></tr><tr><td valign="bottom">All</td><td valign="bottom">16.55</td><td valign="bottom">8.39</td><td valign="bottom">9.55</td><td valign="bottom">11.70</td><td valign="bottom">13.10</td><td valign="bottom">15.02</td><td valign="bottom">35.53</td></tr><tr><td valign="bottom">BC Surveillance</td><td valign="bottom">18.00</td><td valign="bottom">8.72</td><td valign="bottom">9.68</td><td valign="bottom">12.70</td><td valign="bottom">13.48</td><td valign="bottom">14.95</td><td valign="bottom">32.23</td></tr><tr><td valign="bottom">BC early detection</td><td valign="bottom">15.86</td><td valign="bottom">8.67</td><td valign="bottom">10.09</td><td valign="bottom">11.60</td><td valign="bottom">13.26</td><td valign="bottom">15.17</td><td valign="bottom">27.21</td></tr><tr><td valign="bottom">UTUC cohort</td><td valign="bottom">15.18</td><td valign="bottom">5.97</td><td valign="bottom">6.38</td><td valign="bottom">8.82</td><td valign="bottom">11.16</td><td valign="bottom">14.58</td><td valign="bottom">6.77</td></tr></tbody></table></table-wrap></p><disp-quote content-type="editor-comment"><p>4) Have the authors modeled whether including more, or less than 11 genes + TERT/aneuploidy, would impact performance of the test? Are there ways to improve the design to improve performance?</p></disp-quote><p>This is an excellent question. The genes chosen for the analysis were based on a comprehensive evaluation of the literature on bladder cancer (insufficient data existed for UTUC, but prior publications indicate that the genetic alterations in upper and lower urinary tract cancers are similar). We modeled how additional genes would impact the assay by looking at the inclusion of other amplicons from the top 20 genes contributing to bladder cancer development listed in the COSMIC database. As shown in the figure in Supplementary file 1, the 59 amplicons chosen are above the asymptote in this graph, meaning that more amplicons would not substantially to sensitivity. More amplicons would however, increase the cost and indirectly decrease the sensitivity by decreasing specificity. The reason for this decrease in sensitivity is that the probabilistic models used to interpret rare mutations are rooted in multiple hypothesis testing; the more amplicons studied, the greater the possibility for false positives. The Bonferroni correction is an early example of an approach for dealing with this issue. The new figure illustrates that our choice of amplicons was reasonable. Moreover, the point in the graph (at 59 amplicons) shows that the expected sensitivity was actually realized in the primary bladder cancers that we studied, and was not just theoretical based on expectations from the COSMIC database.</p><p>We have included this graph as a new figure in Supplementary file 1 to illustrate this important concept.</p><disp-quote content-type="editor-comment"><p>5) Why did the authors separate these assays especially that the three assays that make up UroSEEK can be combined in one NGS platform (examples include assays developed by Foundation Medicine, MSK-IMPACT, Oncomine panel, etc.) that can provide more comprehensive genetic analysis on many more genes including mutations and copy number alterations. Some of the currently available NSG platforms can also utilize cfDNA.</p></disp-quote><p>As mentioned in the manuscript, <italic>TERT</italic> promoter region is very CG rich and difficult to amplify. This forced us to exclude it from the rest of the panel and sequence it alone. The Aneuploidy test requires a completely different amplification strategy due the large number of total regions that are assessed (~30,000).</p><p>We are keenly aware of the other tests cited by the reviewers because they are largely based on the strategy we described earlier, using endogenous rather than exogenous molecular barcodes (Kinde reference above). Though it is beyond the scope of our article to discuss their strengths and weaknesses, we note that these other tests are designed to detect relatively high fractions of mutant DNA, much higher than those we observed in many urine samples, at a much larger number of genomic positions. Additionally, they are far more expensive than UroSEEK and not well-suited for screening purposes. UroSEEK is unique so far in that it can assess a relatively small (but adequate) number of amplicons at very high depth and sensitivity at minimal cost.</p><disp-quote content-type="editor-comment"><p>The list of genes in the assay, while includes some of the very commonly mutated genes in bladder cancer, it leaves out other genes that are both relevant and common including for example ARID1A, KDM6A, CDKN1A, STAG2, MLL2/MLL3, etc. Including such genes would very likely improve the assay.</p></disp-quote><p>We again thank the reviewers for this suggestion, but note that the inclusion of these other amplicons would not substantially increase the sensitivity of the assay, as documented by the figure in Supplementary file 1 (and now included in the revised manuscript). We also note that cancers that do not harbor mutations in the 59 individual amplicons evaluated can still be aneuploid and can therefore be detected with the third component of UroSEEK, which detects aneuploidy.</p></body></sub-article></article>